WO2006073472A2 - Kits and processes for removing contaminants from nucleic acids in environmental and biological samples - Google Patents
Kits and processes for removing contaminants from nucleic acids in environmental and biological samples Download PDFInfo
- Publication number
- WO2006073472A2 WO2006073472A2 PCT/US2005/017933 US2005017933W WO2006073472A2 WO 2006073472 A2 WO2006073472 A2 WO 2006073472A2 US 2005017933 W US2005017933 W US 2005017933W WO 2006073472 A2 WO2006073472 A2 WO 2006073472A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleic acid
- flocculant
- sample
- precipitate
- optionally
- Prior art date
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 389
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 386
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 386
- 238000000034 method Methods 0.000 title claims abstract description 307
- 230000007613 environmental effect Effects 0.000 title claims abstract description 60
- 239000012472 biological sample Substances 0.000 title claims abstract description 44
- 239000000356 contaminant Substances 0.000 title claims abstract description 41
- 230000008569 process Effects 0.000 title claims abstract description 37
- 239000000523 sample Substances 0.000 claims abstract description 261
- 239000002689 soil Substances 0.000 claims abstract description 110
- 239000000126 substance Substances 0.000 claims abstract description 99
- 239000000203 mixture Substances 0.000 claims abstract description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 20
- 244000005700 microbiome Species 0.000 claims abstract description 19
- 241001465754 Metazoa Species 0.000 claims abstract description 18
- 235000013305 food Nutrition 0.000 claims abstract description 11
- 239000002244 precipitate Substances 0.000 claims description 107
- 238000003752 polymerase chain reaction Methods 0.000 claims description 73
- 239000006228 supernatant Substances 0.000 claims description 59
- 239000003599 detergent Substances 0.000 claims description 52
- 230000003321 amplification Effects 0.000 claims description 37
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 37
- 108091034117 Oligonucleotide Proteins 0.000 claims description 33
- -1 reef Substances 0.000 claims description 32
- 239000011324 bead Substances 0.000 claims description 31
- 239000000463 material Substances 0.000 claims description 30
- 238000006243 chemical reaction Methods 0.000 claims description 29
- 238000000746 purification Methods 0.000 claims description 29
- 241000196324 Embryophyta Species 0.000 claims description 28
- 239000000306 component Substances 0.000 claims description 26
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 25
- 241000894006 Bacteria Species 0.000 claims description 24
- 239000003795 chemical substances by application Substances 0.000 claims description 24
- 239000002361 compost Substances 0.000 claims description 22
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 21
- 239000000047 product Substances 0.000 claims description 21
- 239000007787 solid Substances 0.000 claims description 21
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 claims description 20
- 239000005695 Ammonium acetate Substances 0.000 claims description 20
- 229940043376 ammonium acetate Drugs 0.000 claims description 20
- 235000019257 ammonium acetate Nutrition 0.000 claims description 20
- 238000001514 detection method Methods 0.000 claims description 20
- 238000012545 processing Methods 0.000 claims description 19
- 125000001453 quaternary ammonium group Chemical group 0.000 claims description 19
- 239000013049 sediment Substances 0.000 claims description 19
- 150000003512 tertiary amines Chemical class 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- 238000009396 hybridization Methods 0.000 claims description 17
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 16
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 15
- 125000002091 cationic group Chemical group 0.000 claims description 15
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims description 14
- 239000004021 humic acid Substances 0.000 claims description 14
- HSEYYGFJBLWFGD-UHFFFAOYSA-N 4-methylsulfanyl-2-[(2-methylsulfanylpyridine-3-carbonyl)amino]butanoic acid Chemical compound CSCCC(C(O)=O)NC(=O)C1=CC=CN=C1SC HSEYYGFJBLWFGD-UHFFFAOYSA-N 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 13
- 229920000642 polymer Polymers 0.000 claims description 13
- 229910021578 Iron(III) chloride Inorganic materials 0.000 claims description 12
- 241000700605 Viruses Species 0.000 claims description 12
- 239000000872 buffer Substances 0.000 claims description 12
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims description 12
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 claims description 12
- 241000233866 Fungi Species 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 11
- 229920002401 polyacrylamide Polymers 0.000 claims description 11
- 238000010839 reverse transcription Methods 0.000 claims description 11
- 231100000765 toxin Toxicity 0.000 claims description 11
- 239000003053 toxin Substances 0.000 claims description 11
- QJZYHAIUNVAGQP-UHFFFAOYSA-N 3-nitrobicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid Chemical compound C1C2C=CC1C(C(=O)O)C2(C(O)=O)[N+]([O-])=O QJZYHAIUNVAGQP-UHFFFAOYSA-N 0.000 claims description 10
- 241000193403 Clostridium Species 0.000 claims description 10
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 10
- 125000000129 anionic group Chemical group 0.000 claims description 10
- 230000003196 chaotropic effect Effects 0.000 claims description 10
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 claims description 10
- 241000193738 Bacillus anthracis Species 0.000 claims description 9
- 102000004190 Enzymes Human genes 0.000 claims description 9
- 108090000790 Enzymes Proteins 0.000 claims description 9
- 238000007834 ligase chain reaction Methods 0.000 claims description 9
- 230000010076 replication Effects 0.000 claims description 9
- 238000005096 rolling process Methods 0.000 claims description 9
- 239000000377 silicon dioxide Substances 0.000 claims description 9
- 229920000936 Agarose Polymers 0.000 claims description 8
- 239000000428 dust Substances 0.000 claims description 8
- 238000006911 enzymatic reaction Methods 0.000 claims description 8
- 239000011521 glass Substances 0.000 claims description 8
- 238000003306 harvesting Methods 0.000 claims description 8
- 239000002773 nucleotide Substances 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 241000244206 Nematoda Species 0.000 claims description 7
- 239000002202 Polyethylene glycol Substances 0.000 claims description 7
- 208000001203 Smallpox Diseases 0.000 claims description 7
- 208000028227 Viral hemorrhagic fever Diseases 0.000 claims description 7
- 238000005119 centrifugation Methods 0.000 claims description 7
- 239000000499 gel Substances 0.000 claims description 7
- 238000002955 isolation Methods 0.000 claims description 7
- 229920003023 plastic Polymers 0.000 claims description 7
- 239000004033 plastic Substances 0.000 claims description 7
- 229920001223 polyethylene glycol Polymers 0.000 claims description 7
- 108091008146 restriction endonucleases Proteins 0.000 claims description 7
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 claims description 6
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 6
- 231100000699 Bacterial toxin Toxicity 0.000 claims description 6
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 6
- 239000004380 Cholic acid Substances 0.000 claims description 6
- 206010014612 Encephalitis viral Diseases 0.000 claims description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 6
- 239000000688 bacterial toxin Substances 0.000 claims description 6
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims description 6
- 235000019416 cholic acid Nutrition 0.000 claims description 6
- 229960002471 cholic acid Drugs 0.000 claims description 6
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims description 6
- 229960003964 deoxycholic acid Drugs 0.000 claims description 6
- 230000029087 digestion Effects 0.000 claims description 6
- 239000002509 fulvic acid Substances 0.000 claims description 6
- 230000002441 reversible effect Effects 0.000 claims description 6
- 229940016590 sarkosyl Drugs 0.000 claims description 6
- 108700004121 sarkosyl Proteins 0.000 claims description 6
- 229940083575 sodium dodecyl sulfate Drugs 0.000 claims description 6
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 claims description 6
- 229940079862 sodium lauryl sarcosinate Drugs 0.000 claims description 6
- ADWNFGORSPBALY-UHFFFAOYSA-M sodium;2-[dodecyl(methyl)amino]acetate Chemical compound [Na+].CCCCCCCCCCCCN(C)CC([O-])=O ADWNFGORSPBALY-UHFFFAOYSA-M 0.000 claims description 6
- 201000002498 viral encephalitis Diseases 0.000 claims description 6
- WZUKKIPWIPZMAS-UHFFFAOYSA-K Ammonium alum Chemical compound [NH4+].O.O.O.O.O.O.O.O.O.O.O.O.[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O WZUKKIPWIPZMAS-UHFFFAOYSA-K 0.000 claims description 5
- 241000191938 Micrococcus luteus Species 0.000 claims description 5
- 229910052782 aluminium Inorganic materials 0.000 claims description 5
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 5
- 238000001962 electrophoresis Methods 0.000 claims description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 5
- 229910052742 iron Inorganic materials 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 229910052751 metal Inorganic materials 0.000 claims description 5
- 239000002184 metal Substances 0.000 claims description 5
- 239000011707 mineral Substances 0.000 claims description 5
- 239000004094 surface-active agent Substances 0.000 claims description 5
- DUIOKRXOKLLURE-UHFFFAOYSA-N 2-octylphenol Chemical compound CCCCCCCCC1=CC=CC=C1O DUIOKRXOKLLURE-UHFFFAOYSA-N 0.000 claims description 4
- 241000186074 Arthrobacter globiformis Species 0.000 claims description 4
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 4
- 241000606126 Bacteroidaceae Species 0.000 claims description 4
- 102000016911 Deoxyribonucleases Human genes 0.000 claims description 4
- 108010053770 Deoxyribonucleases Proteins 0.000 claims description 4
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 claims description 4
- 241000588921 Enterobacteriaceae Species 0.000 claims description 4
- 241000238631 Hexapoda Species 0.000 claims description 4
- 241000588656 Neisseriaceae Species 0.000 claims description 4
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 4
- 241000947836 Pseudomonadaceae Species 0.000 claims description 4
- 239000000919 ceramic Substances 0.000 claims description 4
- 238000004949 mass spectrometry Methods 0.000 claims description 4
- 244000052769 pathogen Species 0.000 claims description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 4
- 201000006266 variola major Diseases 0.000 claims description 4
- 238000003260 vortexing Methods 0.000 claims description 4
- PUKLDDOGISCFCP-JSQCKWNTSA-N 21-Deoxycortisone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2=O PUKLDDOGISCFCP-JSQCKWNTSA-N 0.000 claims description 3
- 241000589013 Alcaligenaceae Species 0.000 claims description 3
- 241000131971 Bradyrhizobiaceae Species 0.000 claims description 3
- 241000190834 Chromatiaceae Species 0.000 claims description 3
- 241000186216 Corynebacterium Species 0.000 claims description 3
- 241000186246 Corynebacterium renale Species 0.000 claims description 3
- 241000186541 Desulfotomaculum Species 0.000 claims description 3
- 241001478891 Filibacter Species 0.000 claims description 3
- FCYKAQOGGFGCMD-UHFFFAOYSA-N Fulvic acid Natural products O1C2=CC(O)=C(O)C(C(O)=O)=C2C(=O)C2=C1CC(C)(O)OC2 FCYKAQOGGFGCMD-UHFFFAOYSA-N 0.000 claims description 3
- 241000589246 Legionellaceae Species 0.000 claims description 3
- 241000192041 Micrococcus Species 0.000 claims description 3
- 241000186359 Mycobacterium Species 0.000 claims description 3
- 241000187654 Nocardia Species 0.000 claims description 3
- 241000206591 Peptococcus Species 0.000 claims description 3
- 241000191992 Peptostreptococcus Species 0.000 claims description 3
- 239000004698 Polyethylene Substances 0.000 claims description 3
- 241000702263 Reovirus sp. Species 0.000 claims description 3
- 241001633102 Rhizobiaceae Species 0.000 claims description 3
- 241000187561 Rhodococcus erythropolis Species 0.000 claims description 3
- 241000606683 Rickettsiaceae Species 0.000 claims description 3
- 241000589971 Spirochaetaceae Species 0.000 claims description 3
- 241000204117 Sporolactobacillus Species 0.000 claims description 3
- 241000870995 Variola Species 0.000 claims description 3
- 239000005420 bog Substances 0.000 claims description 3
- 238000004587 chromatography analysis Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 229940095100 fulvic acid Drugs 0.000 claims description 3
- 239000002663 humin Substances 0.000 claims description 3
- 238000002372 labelling Methods 0.000 claims description 3
- 239000003415 peat Substances 0.000 claims description 3
- 229920000573 polyethylene Polymers 0.000 claims description 3
- 238000004382 potting Methods 0.000 claims description 3
- 239000010802 sludge Substances 0.000 claims description 3
- 239000002364 soil amendment Substances 0.000 claims description 3
- 241001430294 unidentified retrovirus Species 0.000 claims description 3
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 claims description 2
- 208000031872 Body Remains Diseases 0.000 claims description 2
- 241000193163 Clostridioides difficile Species 0.000 claims description 2
- DBXNUXBLKRLWFA-UHFFFAOYSA-N N-(2-acetamido)-2-aminoethanesulfonic acid Chemical compound NC(=O)CNCCS(O)(=O)=O DBXNUXBLKRLWFA-UHFFFAOYSA-N 0.000 claims description 2
- 102000006382 Ribonucleases Human genes 0.000 claims description 2
- 108010083644 Ribonucleases Proteins 0.000 claims description 2
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 claims description 2
- 229920004890 Triton X-100 Polymers 0.000 claims description 2
- 239000013504 Triton X-100 Substances 0.000 claims description 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims description 2
- 238000003556 assay Methods 0.000 claims description 2
- 238000001574 biopsy Methods 0.000 claims description 2
- DDKJQJYTUAWSPY-UHFFFAOYSA-H bis(2,2-dioxo-1,3,2,4-dioxathialumetan-4-yl) sulfate dodecahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.[Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DDKJQJYTUAWSPY-UHFFFAOYSA-H 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 210000001124 body fluid Anatomy 0.000 claims description 2
- 239000010839 body fluid Substances 0.000 claims description 2
- 238000007813 chromatographic assay Methods 0.000 claims description 2
- 238000001976 enzyme digestion Methods 0.000 claims description 2
- 230000002550 fecal effect Effects 0.000 claims description 2
- 231100000640 hair analysis Toxicity 0.000 claims description 2
- 239000000017 hydrogel Substances 0.000 claims description 2
- 239000008235 industrial water Substances 0.000 claims description 2
- 150000002505 iron Chemical class 0.000 claims description 2
- 238000002493 microarray Methods 0.000 claims description 2
- 229920002114 octoxynol-9 Polymers 0.000 claims description 2
- 239000003921 oil Substances 0.000 claims description 2
- 238000007420 radioactive assay Methods 0.000 claims description 2
- 239000011435 rock Substances 0.000 claims description 2
- 210000003296 saliva Anatomy 0.000 claims description 2
- 238000004062 sedimentation Methods 0.000 claims description 2
- 210000000582 semen Anatomy 0.000 claims description 2
- 108020004414 DNA Proteins 0.000 description 117
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 64
- 239000000243 solution Substances 0.000 description 44
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 25
- 241000282414 Homo sapiens Species 0.000 description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 238000000605 extraction Methods 0.000 description 15
- 238000000246 agarose gel electrophoresis Methods 0.000 description 14
- 239000003153 chemical reaction reagent Substances 0.000 description 14
- 238000003757 reverse transcription PCR Methods 0.000 description 14
- 238000012546 transfer Methods 0.000 description 14
- 239000004927 clay Substances 0.000 description 12
- 241000894007 species Species 0.000 description 12
- 108700012359 toxins Proteins 0.000 description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- 210000003608 fece Anatomy 0.000 description 10
- 238000012408 PCR amplification Methods 0.000 description 9
- 239000007983 Tris buffer Substances 0.000 description 9
- 239000008394 flocculating agent Substances 0.000 description 9
- 230000003311 flocculating effect Effects 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 239000010871 livestock manure Substances 0.000 description 9
- 235000013824 polyphenols Nutrition 0.000 description 9
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 9
- 241001112695 Clostridiales Species 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 238000005189 flocculation Methods 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 230000016615 flocculation Effects 0.000 description 7
- 238000000265 homogenisation Methods 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 241000283073 Equus caballus Species 0.000 description 6
- 229940079920 digestives acid preparations Drugs 0.000 description 6
- 230000002255 enzymatic effect Effects 0.000 description 6
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- 108020004635 Complementary DNA Proteins 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- QTANTQQOYSUMLC-UHFFFAOYSA-O Ethidium cation Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 QTANTQQOYSUMLC-UHFFFAOYSA-O 0.000 description 5
- 241001655322 Streptomycetales Species 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 238000010804 cDNA synthesis Methods 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 230000009089 cytolysis Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 241000195493 Cryptophyta Species 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 238000011109 contamination Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 150000008442 polyphenolic compounds Chemical class 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000002797 proteolythic effect Effects 0.000 description 4
- 230000001523 saccharolytic effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 241000186361 Actinobacteria <class> Species 0.000 description 3
- 241000710929 Alphavirus Species 0.000 description 3
- 241000304886 Bacilli Species 0.000 description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 238000007399 DNA isolation Methods 0.000 description 3
- 241000192125 Firmicutes Species 0.000 description 3
- 239000007993 MOPS buffer Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000002123 RNA extraction Methods 0.000 description 3
- 241000206572 Rhodophyta Species 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 229940065181 bacillus anthracis Drugs 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 206010014599 encephalitis Diseases 0.000 description 3
- 229960005542 ethidium bromide Drugs 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 238000003898 horticulture Methods 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000002362 mulch Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 210000003463 organelle Anatomy 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000004576 sand Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- 241000712891 Arenavirus Species 0.000 description 2
- 241000194106 Bacillus mycoides Species 0.000 description 2
- 238000007900 DNA-DNA hybridization Methods 0.000 description 2
- 241000711950 Filoviridae Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 241000199919 Phaeophyceae Species 0.000 description 2
- 102000009097 Phosphorylases Human genes 0.000 description 2
- 108010073135 Phosphorylases Proteins 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 241000187747 Streptomyces Species 0.000 description 2
- 108020004566 Transfer RNA Proteins 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000010009 beating Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 210000003763 chloroplast Anatomy 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000000658 coextraction Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000002223 garnet Substances 0.000 description 2
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 2
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 2
- 238000001821 nucleic acid purification Methods 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000014102 seafood Nutrition 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000012134 supernatant fraction Substances 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- ODWNBAWYDSWOAF-UHFFFAOYSA-N 2,4,4-trimethylpentan-2-yloxybenzene Chemical compound CC(C)(C)CC(C)(C)OC1=CC=CC=C1 ODWNBAWYDSWOAF-UHFFFAOYSA-N 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- 241001443536 Aigialus parvus Species 0.000 description 1
- 241001425781 Antennospora quadricornuta Species 0.000 description 1
- 241000186063 Arthrobacter Species 0.000 description 1
- 241001524194 Arthrobacter agilis Species 0.000 description 1
- 241000185996 Arthrobacter citreus Species 0.000 description 1
- 241000193409 Bacillus azotoformans Species 0.000 description 1
- 241000193749 Bacillus coagulans Species 0.000 description 1
- 241000906059 Bacillus pseudomycoides Species 0.000 description 1
- 241000194103 Bacillus pumilus Species 0.000 description 1
- 241000193388 Bacillus thuringiensis Species 0.000 description 1
- 241000606124 Bacteroides fragilis Species 0.000 description 1
- 241001274890 Boeremia exigua Species 0.000 description 1
- 108030001720 Bontoxilysin Proteins 0.000 description 1
- 208000003508 Botulism Diseases 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 206010006500 Brucellosis Diseases 0.000 description 1
- 241001453380 Burkholderia Species 0.000 description 1
- 241000722910 Burkholderia mallei Species 0.000 description 1
- 206010069747 Burkholderia mallei infection Diseases 0.000 description 1
- 206010069748 Burkholderia pseudomallei infection Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 241001488115 Catenella Species 0.000 description 1
- 240000001817 Cereus hexagonus Species 0.000 description 1
- 241001238286 Chaetomorpha gracilis Species 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 241001647378 Chlamydia psittaci Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000196319 Chlorophyceae Species 0.000 description 1
- 241000195628 Chlorophyta Species 0.000 description 1
- 241001493800 Cladophoraceae Species 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 108010065152 Coagulase Proteins 0.000 description 1
- 241001464948 Coprococcus Species 0.000 description 1
- 241001445332 Coxiella <snail> Species 0.000 description 1
- 241000192700 Cyanobacteria Species 0.000 description 1
- 230000007035 DNA breakage Effects 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 241000825166 Dictyota sp. Species 0.000 description 1
- 241000199915 Dictyotaceae Species 0.000 description 1
- 241001674359 Didymosphaeria enalia Species 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 241000589565 Flavobacterium Species 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 241000589602 Francisella tularensis Species 0.000 description 1
- 201000003641 Glanders Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 241000735546 Halocyphina villosa Species 0.000 description 1
- 241000143682 Hypoxylon Species 0.000 description 1
- 241001524190 Kocuria kristinae Species 0.000 description 1
- 241000191948 Kocuria rosea Species 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 241000193354 Lulworthia Species 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 108700005443 Microbial Genes Proteins 0.000 description 1
- 241000191951 Micrococcus lylae Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 241001524198 Nesterenkonia halobia Species 0.000 description 1
- 241000001468 Nia vibrissa Species 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 241000193418 Paenibacillus larvae Species 0.000 description 1
- 241000194105 Paenibacillus polymyxa Species 0.000 description 1
- 241000178958 Paenibacillus validus Species 0.000 description 1
- 241000206590 Peptococcus niger Species 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010037151 Psittacosis Diseases 0.000 description 1
- 206010037688 Q fever Diseases 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000002278 Ribosomal Proteins Human genes 0.000 description 1
- 108010000605 Ribosomal Proteins Proteins 0.000 description 1
- 240000000528 Ricinus communis Species 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- 241000606697 Rickettsia prowazekii Species 0.000 description 1
- 241000192031 Ruminococcus Species 0.000 description 1
- 241000192023 Sarcina Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 101710084578 Short neurotoxin 1 Proteins 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 241000187398 Streptomyces lividans Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 101710136739 Teichoic acid poly(glycerol phosphate) polymerase Proteins 0.000 description 1
- 208000003217 Tetany Diseases 0.000 description 1
- 101710182223 Toxin B Proteins 0.000 description 1
- 101710182532 Toxin a Proteins 0.000 description 1
- 208000034784 Tularaemia Diseases 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 241000607493 Vibrionaceae Species 0.000 description 1
- 241000589634 Xanthomonas Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003570 air Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- LCQXXBOSCBRNNT-UHFFFAOYSA-K ammonium aluminium sulfate Chemical compound [NH4+].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O LCQXXBOSCBRNNT-UHFFFAOYSA-K 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 229940074375 burkholderia mallei Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 239000002734 clay mineral Substances 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000009264 composting Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 239000005447 environmental material Substances 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000004374 forensic analysis Methods 0.000 description 1
- 229940118764 francisella tularensis Drugs 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000011331 genomic analysis Methods 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000003505 heat denaturation Methods 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010249 in-situ analysis Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 244000000056 intracellular parasite Species 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 201000004015 melioidosis Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 238000013048 microbiological method Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 201000000901 ornithosis Diseases 0.000 description 1
- 230000033116 oxidation-reduction process Effects 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 230000000243 photosynthetic effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 125000003410 quininyl group Chemical group 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 229940046939 rickettsia prowazekii Drugs 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 238000010809 targeting technique Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 206010061393 typhus Diseases 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6848—Nucleic acid amplification reactions characterised by the means for preventing contamination or increasing the specificity or sensitivity of an amplification reaction
Definitions
- the invention provides methods and compositions, e.g., kits, for removing contaminants from nucleic acids in a sample, e.g., environmental or biological samples such as soil, food, plant, animal, microorganism or water samples.
- the invention provides methods and compositions, e.g., kits, for isolating nucleic acids from samples, including environmental or biological samples such as soil, food, plant, animal, microorganism or water samples.
- the invention relates to methods and compositions for detecting organisms, e.g., microorganisms, in a sample, e.g., an environmental or a biological sample.
- nucleic acids isolated using the kits and methods of the invention are useful for performing a variety of processes applicable to agriculture, forensics, zoology and combating bioterrorism.
- these nucleic acids are useful in the areas of molecular biological applications, including, for example, analytical, cloning, diagnostic and detection in the fields of agriculture, horticulture, forestry, forensics, biological research, organism and sample composition identification and characterization.
- Nucleic acid sequences have a wide variety of applications in the field of molecular biology. They are a valuable tool in many analytical and application techniques used in the field of molecular biology, health and medicine (gene therapy, diagnostics, recombinant protein expression), bioterrorism (agent detection and analysis), forensics, space science, and food science. Some examples of these techniques include genotyping microorganisms, DNA fingerprinting plants and animals, detecting pathogens and beneficial microorganisms in soils, water, plants and animals, forensic identification of biological samples and environmental samples contaminated with different biological entities. All these techniques are based on identifying a specific sequence of nucleic acid in either a biological sample, such as a microorganism, plant tissues or animal tissues, or in any environment capable of supporting life.
- Identifying target nucleic acid sequences directly in biological samples and in environmental samples has the advantages of speed, accuracy, high-throughput and a low limit of detection to picogram or femtogram quantities of nucleic acids.
- the target nucleic acid sequence in order to be used as a diagnostic tool in such applications, should be free of contaminants that inhibit PCR and other downstream applications. These contaminants are often from the groups that include polyphenols, polysaccharides and humic substances.
- PCR polymerase chain reaction
- PCR polymerase chain reaction
- nucleic acid extraction methods suffer from compounded inefficiencies of DNA sorption to soil surfaces and co-extraction of enzymatic inhibitors from soils. Both the clay and organic fractions of soil affect DNA isolation and purification. Clay has a tendency to bind DNA adsorptively, whereas humic polymers found in the organic fraction tend to co-purify with DNA during the extraction procedure. The higher the montmorillonitic clay and organic matter content, the higher the buffering capacity of the soil system and also greater the amount of DNA adsorbed to the soil particles. Thus methods developed for a particular soil type with a clay:organic ratio may not work for any other soil type with different clay:organic ratio.
- Compost may have a variety of additional organic compounds that may co-purify with DNA and inhibit enzymatic manipulations of the DNA.
- An additional concern when isolating microbial DNA from compost is that plant material in various stages of decomposition may be present in significant concentrations in compost.
- Studies of higher organisms such as fungi, plants and animals, direct nucleic acid isolations are still plagued with quality issues.
- pigments and cell wall components such as chitins and polysaccharides will inhibit PCR.
- humic acids humic acids
- FA fulvic acids
- Humic acids are soluble in alkaline pH and precipitate with hydrochloric or sulphuric acids at pH 1.0 to 2.0, while fulvic acids remain in solution even at acidic pH (Stevenson, 1994).
- DNA extracts from soils showing brown coloration are indicative of contamination with humic like substances. These brown compounds cannot be easily removed from DNA extracts.
- Size-exclusion chromatography includes the use of SEPHADEX G-200TM or MICROSPIN S-400 HRTM, while water-insoluble PVPP and water-soluble polyvinylpyrrolidone (PVP) as humic acid-binding agents have also been reported.
- the invention provides methods and compositions, e.g., kits, for removing contaminants from nucleic acids in a sample, e.g., environmental or biological samples such as soil, food (e.g., for inspections), plant, animal, microorganism or water samples.
- a sample e.g., environmental or biological samples such as soil, food (e.g., for inspections), plant, animal, microorganism or water samples.
- the methods and compositions of the invention are used to remove those contaminants in the sample that can impede or inhibit a nucleic acid amplification reaction.
- the methods and compositions of the invention are used to increase the accuracy and/or efficiency of nucleic acid (e.g., RNA-DNA or DNA-DNA) hybridization reactions, including amplification reactions such as PCR and RT-PCR).
- the invention also provides methods and compositions, e.g., kits, for isolating nucleic acids from samples, including environmental or biological samples.
- the invention is used with flocculating materials in purifying DNA and RNA from a wide variety of samples, e.g., biological or environmental samples, such as soil, food (e.g., meat, vegetables and the like; e.g., for determining contamination of food, including meat, seafood, vegetables, fruit and the like), plant, animal, microorganism or water samples.
- the methods and compositions of the invention can be used for isolating nucleic acids from environmental and biological samples free from contaminating substances that inhibit PCR, RT-PCR and other downstream applications in molecular biology.
- the method comprises contacting the flocculant with the contaminants present along with the nucleic acids at a specified step in the protocol.
- the method is scaleable and exemplary embodiments include integrating the method into a nucleic acid purification process and applying the method to remove contaminants from existing purified nucleic acids.
- the method has applications in agriculture, diagnostics, horticulture, forestry, forensics, combating bioterrorism and other areas where contaminant-free nucleic acid is used.
- the present invention is directed to methods and kits for obtaining nucleic acids from a wide variety of biological and environmental samples in such a way that the isolated nucleic acids are free of contaminating materials, mainly polyphenols, polysaccharides and humic substances.
- An exemplary embodiment of this invention is the use of a flocculating material at a specific step in the protocol where the use of the flocculating material improves significantly the final purity of the isolated DNA and RNA as opposed to the existing art in the use of flocculating materials.
- the invention provides methods for isolating a nucleic acid from a sample comprising: (a) releasing a nucleic acid into the sample medium; (b) contacting the sample medium with at least one flocculant after the nucleic acid is released from the sample; and (c) separating the nucleic acid from the flocculant, wherein optionally the method further comprises purifying the nucleic acid after step (c).
- the invention provides methods for isolating a nucleic acid from a sample comprising: (a) releasing a nucleic acid into the sample medium and comprising a step of adding a first flocculant to the processed, unprocessed, preserved, freshly isolated, crude or unrefined sample medium; (b) contacting the sample medium with a second flocculant after the nucleic acid is extracted from the processed, unprocessed, preserved, freshly isolated, crude or unrefined sample; and (c) separating the nucleic acid from the second flocculant, wherein optionally the method further comprises purifying the nucleic acid after step (c).
- the invention provides methods and kits for removing contaminants from a nucleic acid-comprising sample, wherein the contaminants inhibit (partially or completely) amplification or hybridization of nucleic acids in the sample, the method comprising the steps of: (a) contacting the nucleic acid-comprising sample with at least one flocculant to form a flocculant precipitate; and (b) separating the nucleic acid from the flocculant precipitate, wherein in one aspect (optionally) the method further comprises purifying or isolating the nucleic acid after step (b), and in one aspect (optionally) the sample is an unprocessed, preserved, freshly isolated, crude or unrefined sample, or, the sample is broken up, denatured or disrupted before contacting with the flocculant.
- the invention also provides methods and kits for removing contaminants from a nucleic acid-comprising sample, wherein the contaminants inhibit (partially or completely) amplification or hybridization of nucleic acids in the sample, the method comprising the steps of: (a) contacting the nucleic acid-comprising sample with at least a first flocculant to form a first flocculant precipitate, wherein in one aspect (optionally) the sample is an unprocessed, preserved, freshly isolated, crude or unrefined sample, or, the sample is broken up, denatured or disrupted before contacting with the flocculant; (b) separating the nucleic acid from the first flocculant precipitate; (c) contacting the nucleic acid with a second flocculant to form a flocculant precipitate; and (d) separating the nucleic acid from the second flocculant precipitate, wherein in one aspect (optionally) the method or kit further comprises purifying the nucleic acid after step (d).
- any method or kit of the invention can also be used to remove one or more contaminant(s) from a nucleic acid-comprising sample to facilitate a desired enzymatic or detection reaction, e.g., a ligase or phosphorylase reaction (e.g., to remove a composition in the sample that slows, inhibits or otherwise interferes with the desired enzymatic or detection reaction or process).
- a desired enzymatic or detection reaction e.g., a ligase or phosphorylase reaction
- a composition in the sample that slows, inhibits or otherwise interferes with the desired enzymatic or detection reaction or process.
- the invention provides methods and kits for selectively removing compounds from a nucleic acid-comprising sample, wherein the compounds inhibit (partially or completely) amplification or hybridization of nucleic acids in the sample, the method comprising the steps of: (a) contacting the nucleic acid-comprising sample with at least a first flocculant to form a flocculant precipitate, wherein in one aspect (optionally) the sample is an unprocessed, preserved, freshly isolated, crude or unrefined sample, or, the sample is broken up, denatured or disrupted before contacting with the at least a first flocculant; (b) separating the nucleic acid from the first flocculant precipitate; (c) contacting the nucleic acid with a second flocculant to form a second flocculant precipitate; and (d) separating the nucleic acid from the second flocculant precipitate, wherein in one aspect (optionally) the method or kit further comprises purifying the nucleic acid after step
- the invention also provides methods and kits for selectively removing compounds from a nucleic acid-comprising sample, wherein the compounds inhibit (partially or completely) amplification or hybridization of nucleic acids in the sample, the method comprising the steps of: (a) processing the sample to break up, denature or disrupt the sample before contacting it with a flocculant, wherein the processing treatment comprises mixing or contacting the sample with a solution comprising a chaotropic agent (e.g., guanidium chloride), a detergent (e.g., SDS, see further examples, below), a buffer, a homogenizing agent or a combination thereof; (b) contacting the nucleic acid-comprising sample with at least a first flocculant to form a flocculant precipitate, wherein in one aspect (optionally) the contacting comprises mixing or vortexing the flocculant and the sample; (c) separating a nucleic acid-comprising solution from the first flocculant precipitate, where
- any method or kit of the invention can also be used to remove one or more contaminant(s) from a nucleic acid-comprising sample to facilitate a desired enzymatic or detection reaction or process, e.g., a ligase or phosphorylase reaction (e.g., to remove a composition in the sample that slows, inhibits or otherwise interferes with the desired enzymatic or detection reaction).
- a desired enzymatic or detection reaction or process e.g., a ligase or phosphorylase reaction (e.g., to remove a composition in the sample that slows, inhibits or otherwise interferes with the desired enzymatic or detection reaction).
- the invention provides methods and kits for amplifying, hybridizing, isolating or purifying from a nucleic acid-comprising sample, the method comprising the steps of: (a) processing the sample to break up, denature or disrupt the sample before contacting it with a flocculant, wherein the processing treatment comprises mixing or contacting the sample with a solution comprising a chaotropic agent, a detergent, a buffer, a homogenizing agent or a combination thereof; (b) contacting the nucleic acid-comprising sample with at least a first flocculant to form a flocculant precipitate, wherein the contacting comprises mixing or vortexing the flocculant and the sample, wherein in one aspect (optionally) the first flocculant comprises an ammonium acetate; (c) separating a nucleic acid-comprising solution from the first flocculant precipitate, wherein the separating comprises centrifuging the flocculant and the sample and harvesting a nucleic acid-com
- the invention provides methods and kits for purifying, isolating, hybridizing or amplifying a nucleic acid from a sample comprising: (a) releasing a nucleic acid into the sample medium; (b) contacting the sample medium with at least one flocculant after the nucleic acid is released from the sample; (c) separating the nucleic acid from the flocculant, wherein in one aspect (optionally) the method or kit further comprises purifying, hybridizing isolating or amplifying the nucleic acid after step (c).
- the invention provides methods and kits for isolating a nucleic acid from a sample comprising: (a) extracting a nucleic acid from the sample; (b) contacting the nucleic acid with at least one flocculant after the nucleic acid is extracted from the sample; and (c) separating the nucleic acid from the flocculant, wherein in one aspect (optionally) the method or kit further comprises purifying the nucleic acid after step (c).
- the invention provides methods and kits for purifying, isolating, amplifying or hybridizing a nucleic acid in a sample comprising: (a) extracting a nucleic acid from the sample comprising a step of adding a first flocculant to: (i) an unprocessed, preserved, freshly isolated, crude or unrefined sample, or (ii) a processed sample, wherein the processing comprises breaking up, denaturing or disrupting the sample before contacting it with the first flocculant, wherein in one aspect (optionally) the processing treatment comprises mixing or contacting the sample with a solution comprising a chaotropic agent, a detergent, a buffer, a homogenizing agent or a combination thereof, such that a flocculant precipitate and a nucleic acid-comprising supernatant is formed; (b) removing the flocculant precipitate from the nucleic acid-comprising supernatant, wherein in one aspect (optionally) the separating comprises centrifuging the sample to
- the invention provides methods and kits for purifying, isolating, amplifying or hybridizing a nucleic acid in a sample comprising: (a) extracting a nucleic acid from the sample comprising a step of adding a first flocculant to: (i) an unprocessed, preserved, freshly isolated, crude or unrefined sample, or (ii) a processed sample, wherein the processing comprises breaking up, denaturing or disrupting the sample before contacting it with the first flocculant, and the processing treatment comprises mixing or contacting the sample with a solution comprising a chaotropic agent, a detergent, a buffer, a homogenizing agent or a combination thereof, such that a flocculant precipitate and a nucleic acid-comprising supernatant is formed, wherein in one aspect (optionally) the first flocculant comprises ammonium acetate; (b) removing the flocculant precipitate from the nucleic acid-comprising supernatant, wherein the separating
- the flocculant comprises a cationic chemical substance, an anionic chemical substance, a zwitterionic chemical substance, a non-charged chemical substance or a combination thereof.
- the cationic, anionic, zwitterionic or non-charged substance comprises a quaternary ammonium or tertiary amine containing polymer.
- the flocculant is selected from the group consisting of ammonium acetate, magnesium chloride (MgCl 2 ), ferric chloride (FeCl 3 ), a salt of iron, a salt of aluminum, calcium chloride (CaCl 2 ), a polyacrylamide, aluminum ammonium sulfate, derivatives thereof, and a combination thereof.
- the methods of the invention can further comprise detecting or characterizing a purified, isolated, amplified or hybridized nucleic acid.
- the nucleic acid is detected by a nucleic acid amplification reaction, immobilization on a solid support, hybridization, restriction enzyme digestion, RNase digestion, reverse transcription, DNAse digestion, electrophoresis, chromatography or a combination thereof.
- the nucleic acid amplification reaction comprises a detection method, a polymerase chain reaction (PCR), a reverse transcription, a rolling circle replication, a ligase-chain reaction, a nucleic acid labeling or tagging reaction, derivative methods thereof or a combination thereof.
- the methods of the invention can further comprise identifying an organism or nucleic acid component in the sample.
- the organism can be identified by identifying or characterizing the purified, isolated, amplified or hybridized nucleic acid.
- the detected organism or nucleic acid component can be derived from a microorganism, an animal, a plant, an insect, a yeast, a virus, a phage, a nematode, a bacteria or a fungi.
- the bacteria detected can comprise a gram positive or a gram negative bacteria.
- the sample comprises an environmental or a biological sample.
- the environmental or biological sample can comprise a sample derived from an animal, animal remains, a food, a microorganism, a plant or its components, soil, sediment, rock, reef, sludge, compost, decomposing biological matter, a biopsy, a histological sample, a semen sample, a blood or saliva sample, any body fluid sample, a hair sample, a skin sample, a fecal sample, archaeological remains, a peat bog, compost, oil, water, terrestrial water or subterranean water, atmospheric and industrial water, dust, urban dust, commercial potting mixtures or soil amendments, deep sea vents, or air, wherein in one aspect (optionally) the sample is processed by mechanical filtering, sedimentation or centrifugation.
- the nucleic acid comprises an RNA (e.g., mRNA, tRNA, rRNA, iRNA) or a DNA or a combination thereof.
- RNA e.g., mRNA, tRNA, rRNA, iRNA
- any method or kit of the invention can comprise the step of extracting a nucleic acid from the sample, comprising a step of homogenizing a processed, an unprocessed, freshly isolated, preserved, crude or unrefined sample.
- the sample is homogenized by contacting the sample with a mechanical force, shear force, sound vibration, mechanical vibration or a vortex or vortex adapter (e.g., Vortex Adapter, MoBio, Carlsbad, CA), wherein in one aspect (optionally) the mechanical or shear force comprises used of a glass, a ceramic, a metal, a mineral or a plastic material or a combination thereof, and in one aspect (optionally) the material is in the form of a bead.
- a mechanical force e.g., Vortex Adapter, MoBio, Carlsbad, CA
- the mechanical or shear force comprises used of a glass, a ceramic, a metal, a mineral or a plastic material or a combination thereof, and in one aspect (optionally) the material is
- the method or kit further comprises adding a homogenizing material to the sample for the homogenizing step, wherein in one aspect (optionally) the homogenizing material comprises a glass, a ceramic, a metal, a mineral, a plastic or a combination thereof.
- the nucleic acid can extracted from the sample by a step comprising contacting the sample with a liquid or a composition comprising a detergent or a surfactant or a combination thereof.
- the detergent can be selected from the group consisting of sodium dodecyl sulfate (SDS), sarkosyl, sodium lauryl sarcosinate, cetyltrimethyl ammonium bromide (CTAB), cholic acid, deoxycholic acid, benzamidotaurocholate (BATC), octyl phenol polyethoxylate, polyoxyethylene sorbitan monolaurate, tert-octylphenoxy poly(oxyethylene)ethanol, 1 ,4-piperazinebis-(ethanesulfonic acid), N-(2-acetamido)-2-aminoethanesulfonic acid, polyethylene glycol tert-octylphenyl ether (Triton ® X-100), (SDS), s
- the flocculant does not substantially precipitate the nucleic acid. In one aspect, the flocculant precipitates some but not all of the nucleic acid (e.g., at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more of the nucleic acid is lost in the precipitate, or, alternatively 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more of the nucleic acid remains in a supernatant and is recovered, amplified, purified or hybridized and the like).
- the flocculant precipitates some but not all of the nucleic acid (e.g., at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more of the nucleic acid is lost in the precipitate, or, alternatively 50%, 60%, 70%, 75%, 80%, 85%,
- the flocculant substantially precipitates the nucleic acid, hi one aspect, the flocculant precipitates one or more substances selected from the group consisting of a humic acid, a fulvic acid and humin. In one aspect, the flocculant is separated from the nucleic acid by contacting the flocculant and nucleic acid with a solid support under conditions in which the nucleic acid selectively binds to the solid support.
- the solid support comprises or consists of a glass, an agarose, a plastic, a silica, a polyacrylamide, a hydrogel or a gel.
- the methods or kits or the invention can further comprise amplifying the nucleic acid or a portion thereof after the step of separating the flocculant or the flocculant precipitate from the nucleic acid (after the step of separating either the first and/or the second flocculant precipitate).
- the nucleic acid is amplified using a polymerase chain reaction (PCR) procedure, rolling circle replication, ligase-chain reaction or derivative methods thereof.
- PCR polymerase chain reaction
- the nucleic acid separated from the flocculant or the flocculant precipitate is substantially free of a substance that inhibits a polymerase chain reaction procedure.
- the nucleic acid comprises an RNA, and the RNA is reverse transcribed after the flocculant or the flocculant precipitate is separated from the nucleic acid.
- the nucleic acid is contacted with a restriction enzyme after the flocculant or the flocculant precipitate is separated from the nucleic acid.
- the nucleic acid (e.g., isolated, purified or amplified by or after using a method or kit of the invention) is analyzed by mass spectrometry; agarose, capillary or polyacrylamide electrophoresis; hybridization; an array; a microarray; an enzymatic reaction; a fluorescent assay; a radioactive assay; a chromatographic assay; or, a combination thereof, after the flocculant or the flocculant precipitate is separated from the nucleic acid.
- the nucleic acid is contacted with one or more oligonucleotides after the flocculant or the flocculant precipitate is separated from the nucleic acid.
- one or more of the oligonucleotides hybridizes to the nucleic acid.
- a nucleic acid e.g., isolated, purified or amplified by or after using a method or kit of the invention
- a nucleic acid is immobilized to a solid surface or is hybridized to a nucleic acid immobilized on a solid surface after the flocculant or the flocculant precipitate is separated from the nucleic acid.
- the invention provides method or kits for post-isolation purification of a nucleic acid isolated by an existing method from an environmental or a biological sample that did not yield a detectable amplification product in a polymerase chain reaction (PCR) process, comprising (a) contacting the isolated nucleic acid with flocculant; and in one aspect (optionally) contacting the isolated nucleic acid with a second flocculant; and (c) separating the nucleic acid from the flocculant.
- PCR polymerase chain reaction
- the invention provides method or kits for post-isolation purification or amplification of a nucleic acid extracted from an environmental or a biological sample, wherein the isolated nucleic acid does not yield a detectable amplification product in an amplification reaction, and in one aspect (optionally) the amplification reaction is a polymerase chain reaction (PCR), comprising (a) adding a sufficient amount of a first flocculant to the isolated sample to generate a flocculant precipitate and a nucleic acid-comprising supernatant; (b) removing the flocculant precipitate from the nucleic acid-comprising supernatant; and, (c) purifying or amplifying the nucleic acid from the nucleic acid-comprising supernatant.
- PCR polymerase chain reaction
- the methods can further comprise the steps of contacting the nucleic acid-comprising supernatant generated in step (b) with a second flocculant to generate a second flocculant precipitate and second nucleic acid-comprising supernatant, and the nucleic acid is purified or amplified from the second nucleic acid-comprising supernatant.
- the methods can further comprise contacting the isolated sample or nucleic acid, or the first or second flocculant precipitate, with a detergent. In one aspect, a substantial amount of the detergent is separated from the nucleic acid before the nucleic acid is contacted with the flocculant, or before the nucleic acid is purified or amplified.
- the invention provides method or kits for releasing DNA from a sample comprising: (a) releasing a DNA from the sample comprising a step of adding a first flocculant comprising a quaternary ammonium or tertiary amine containing polymer to a processed, an unprocessed, preserved, freshly isolated, crude or unrefined sample medium, to generate a first flocculant precipitate and a first DNA-comprising supernatant, wherein in one aspect (optionally) the quaternary ammonium or tertiary amine comprises an ammonium acetate; and (b) contacting the first DNA-comprising supernatant with a second flocculant comprising a quaternary ammonium or tertiary amine to generate a second flocculant precipitate and a second DNA-comprising supernatant, wherein in one aspect (optionally) the quaternary ammonium or tertiary amine comprises an aluminum ammonium s
- the invention provides method or kits for releasing RNA from a sample comprising: (a) releasing an RNA from the sample comprising a step of adding a first flocculant comprising a quaternary ammonium or tertiary amine containing polymer to an processed, unprocessed, preserved, freshly isolated, crude or unrefined sample medium, to generate a first flocculant precipitate and a first RNA-comprising supernatant, wherein in one aspect (optionally) the quaternary ammonium or tertiary amine comprises an ammonium acetate; (b) contacting the first RNA-comprising supernatant with a second flocculant comprising a quaternary ammonium or tertiary amine to generate a second flocculant precipitate and a second RNA-comprising supernatant, wherein in one aspect (optionally) the method comprises further comprises after step (b) contacting the nucleic acid with a buffer comprising
- kits for isolating a nucleic acid from a samples comprising at least one flocculant and instructions describing a method for use according to any of the methods of the invention.
- the flocculant comprises an anionic, cationic, zwitterionic or uncharged chemical substance or combination thereof, wherein in one aspect (optionally) the cationic substance comprises a quaternary ammonium or tertiary amine containing polymer.
- the flocculant can be selected from the group consisting of ammonium acetate, magnesium chloride (MgCl 2 ), ferric chloride (FeCl 3 ), an iron salt or an aluminum salt, calcium chloride (CaCl 2 ), a polyacrylamide, aluminum ammonium sulfate and derivatives thereof.
- the kit further comprises a detergent or a surfactant.
- the detergent is selected from the group consisting of sodium dodecyl sulfate (SDS), sarkosyl, sodium lauryl sarcosinate, cetyltrimethyl ammonium bromide (CTAB), cholic acid, deoxycholic acid, benzamidotaurocholate (BATC), octyl phenol polyethoxylate, polyoxyethylene sorbitan monolaurate, tert-octylphenoxy poly(oxyethylene)ethanol , polyethylene glycokert-octylphenyl ether (Triton X-100), (1,1,3,3-tetramethylbutyl) phenyl- polyethylene glycol (Triton ® X-l 14) and a combination thereof.
- the kit further comprises a homogenizing material (e.g., a bead).
- a bead wherein in one aspect (optionally) the bead is a homogenizing bead.
- the kit further comprises one or more solutions or buffers (e.g.,
- the kit comprises instructions describing a method for obtaining a sample for processing.
- the kit further comprises one or more vessels or containers, e.g., tube vessels (e.g., test tube, capillary, Eppendorf tube) useful for performing the method of use.
- the kit further comprises one or more oligonucleotides, and in one aspect (optionally) free nucleotides, and in one aspect (optionally) sufficient free nucleotides to carry out a PCR reaction, a rolling circle replication, a ligase-chain reaction, a reverse transcription, a nucleic acid labeling or tagging reaction, or derivative methods thereof.
- the kit further comprises at least one enzyme, wherein in one aspect (optionally) the enzyme is a polymerase.
- the kit further comprises one or more oligonucleotides, free nucleotides and at least one polymerase or enzyme capable of amplifying a nucleic acid in a PCR reaction, a rolling circle replication, a ligase-chain reaction, a reverse transcription or derivative methods thereof.
- the one or more oligonucleotides can specifically hybridize to a nucleic acid from a microorganism, an animal, a plant, an insect, a yeast, a virus, a phage, a nematode, a bacteria or a fungi.
- the one or more oligonucleotides can specifically hybridize to a nucleic acid from a Bacillus spp., a Clostridium spp., a Sporolactobacillus spp.; a Sporocarcina spp.; a Filibacter spp.; a Caryophanum spp.; a Desulfotomaculum spp.; a Corynebacterium spp.; a Micrococcus spp.; a Mycobacterium spp.; a Nocardia spp.; a Peptococcus spp.; a Peptostreptococcus spp., or a Gram negative bacteria from a family comprising Acetobacteriaceae, Alcaligenaceae, Bacteroidaceae, Chromatiaceae, Enterobacteriaceae, Legionellaceae, Neisseriaceae, Nitrobacteriaceae, Pseudomo
- the one or more oligonucleotides can specifically hybridize to a nucleic acid from B. anthracis, A. globiformis, B. subtilis, C. renale, C. difficile, M. luteus, or R. erythropolis.
- the one or more oligonucleotides can specifically hybridize to a nucleic acid from a virus, e.g., a variola, varicella, reovirus, retroviruses, HIV, HIV-I, viral hemorrhagic fevers, Ebola, Marburg, Machupo, Lassa, Variola major, viral encephalitis, any of the pathogens listed in Table 1.
- a virus e.g., a variola, varicella, reovirus, retroviruses, HIV, HIV-I, viral hemorrhagic fevers, Ebola, Marburg, Machupo, Lassa, Variola major, viral encephalitis, any of the pathogens listed in Table 1.
- kits for the detection of a spore or bacterial toxin comprising at least one flocculant and instructions describing a method for use according to any method of the invention, wherein the kit is used to detect organisms that produce the spore or toxin, wherein optionally the toxin is a bacterial toxin.
- the invention provides kits for the detection of a biohazard comprising at least one flocculant and instructions describing a method for use according to any method of the invention, wherein the kit is used to detect organisms that produce a biohazard agent, wherein optionally the biohazard agent is a bacterial toxin.
- Figure 1 illustrates an agarose gel electrophoresis showing DNA purified by an exemplary method of the invention, as described in Example 1 , below.
- Figure 2 illustrates an agarose gel electrophoresis showing PCR amplified total genomic DNA isolated in Figure 1 , as described in Example 1 , below.
- Figure 3 illustrates an agarose gel electrophoresis showing a comparison of PCR amplification of eubacterial DNA isolated using a commercially available kit representative of the existing art, as described in Example 1, below.
- Figure 4 illustrates an agarose gel electrophoresis showing total genomic DNA was isolated from different soil samples, as described in Example 2, below.
- Figure 5 illustrates an agarose gel electrophoresis showing total genomic DNA PCR amplified using primers to the Bacillus spp., as described in Example 2 and 3, below.
- Figure 6 illustrates an agarose gel electrophoresis showing total genomic DNA PCR amplified using primers to the Streptomyces spp., as described in Examples 2 and 3, below.
- Figures 7 and 8 illustrates agarose gel electrophoreses showing nucleic acid isolated from soil samples (see Table 1 , Example 3) and tested by PCR, as described in Example 3, below.
- Figure 9 illustrates an agarose gel electrophoresis showing RNA isolated from 8 different soil types, as noted in Table 2, Example 3, as described in Example 3, below below.
- Figures 10 and 11 illustrate agarose gel electrophoreses showing RT-PCR amplification of total RNA from a soil sample with a primer set specific for microorganisms belonging to Bacilli group and Streptomycetes group, respectively.
- the invention relates to methods and compositions for detecting and/or isolating nucleic acids, and/or for detecting organisms, e.g., microorganisms, in a sample, e.g., an environmental or biological samples.
- the invention provides methods and compositions, e.g., kits, for isolating nucleic acids from sources containing contaminating substances that interfere with use of the purified nucleic acid in subsequent applications.
- the invention provides methods and kits for purifying nucleic acids from environmental or biological samples to be free of contaminants that may or usually inhibit an enzymatic reaction, such as an amplification reaction, e.g., PCR.
- the biological samples include but are not limited to tissues from human, animal, plant, and the environmental samples include but are not limited to soil, sediment, sludge, decomposing biological matter, archaeological remains, peat bogs, compost and water that are terrestrial or subterranean in origin.
- Nucleic acids isolated using the kits and methods of the invention may be used in the areas of molecular biological application, including, for example, analytical, cloning, diagnostic and detection in the fields of agriculture, horticulture, forestry, forensics, biological research, organism and sample composition identification, characterization and combating bioterrorism.
- the invention provides compositions and methods for isolating or extracting nucleic acids, e.g., DNA and/or RNA, by adding flocculating agents at a specific step to purify DNA and RNA from contaminants in a sample, e.g., an environmental or biological sample.
- a sample e.g., an environmental or biological sample.
- the compositions and methods of the invention combine the properties of two reagents, ammonium acetate or equivalents, and aluminum ammonium sulfate or equivalents, to remove contaminants from DNA in (at least) two different steps.
- ammonium acetate or equivalent is added to the crude environmental or biological sample (e.g., a soil mix) remove the majority of contaminants while leaving the DNA present.
- ammonium aluminum sulfate or equivalent is added next to remove the remaining contaminants, including humic substances, e.g., from soil and phenolics from plants. While the invention is not limited by any particular mechanism of action, in one aspect the interaction between the flocculating agent and the non-nucleic acid components results in a targeted mass action precipitation of the contaminating material. In one aspect, homogenization beads are used in the procedure (also noting that in one aspect a procedure of the invention does not use homogenization - which may result in a lower DNA yield as compared to using homogenization beads, or equivalent).
- the invention provides compositions and methods for isolating or extracting DNA comprising use of two flocculating agents at separate steps in a DNA purification process to remove PCR inhibiting substances while selectively maintaining the DNA concentration.
- the invention uses flocculating agents in a step-wise approach: first using ammonium acetate or equivalent (e.g., as in step 5 in Example 1, or step 3, of Example 2, below) to remove the majority of contaminating substances and to enhance the removal efficiency of the second flocculating agent, aluminum ammonium sulfate or equivalent, added next (e.g., as in step 6 in Example 1, or step 4, of Example 2, below).
- aluminum ammonium sulfate or equivalent is used as a flocculating agent to remove humic and phenolic substances from soil and plants in a process to purify DNA from contaminants in a sample, such as an environmental or biological sample.
- the invention further comprises use of charged chemical components added to a solution to remove contaminants from DNA through fiocculation during purification.
- RNA is isolated using exemplary methods of the invention (see Example 4, below), and the invention utilizes aluminum ammonium sulfate in Step 3 (Solution SR3) as a flocculent prior to the addition of phenol (containing chloroform and isoamyl alcohol [25:24:1]).
- Phenol then selectively removes the remaining proteins, but more importantly for soil and plants, removes the clay and phenolics from solution.
- Clay is unwanted in subsequent steps for two reasons, it selectively associates with RNA and can lead to purification losses and it inhibits (either through association with RNA or interaction with enzymes) use in downstream applications.
- exemplary methods of the invention for isolating RNA comprise: use of a flocculating agent (aluminum ammonium sulfate) to remove the majority of contaminating substances prior to adding a second reagent (phenol) to enhance the removal efficiency and selectivity of the second agent; a process to remove RT-PCR inhibiting substances using a flocculent in a process that maintains the RNA concentration; the use of phenol as a purification step to remove clay from RNA in soil samples with the intent of increasing the purification efficiency and removes contaminants; the use of chromatography as a purification method by binding RNA, DNA and contaminating substances to a solid phase matrix and selectively eluting the RNA under conditions that retain DNA and contaminating substances (humic substances in soil and phenolics in plants); the use of a charged chemical component added to solution to remove contaminants from RNA through flocculation during purification; or a combination thereof.
- a flocculating agent aluminum ammonium sulfate
- compositions e.g., kits
- methods for isolating a nucleic acid from environmental or biological samples comprising extracting a nucleic acid from the sample; and contacting the nucleic acid with a flocculant after the nucleic acid is released or extracted from the soil.
- nucleic acid is separated from the flocculant.
- the invention provides a method for separating a nucleic acid already extracted from environmental or biological samples from contaminating substances, including polymerase chain reaction (PCR)-inhibiting substances and/or nucleic acid hybridization inhibiting substances (e.g., DNA-DNA hybridization), comprising contacting a nucleic acid extracted from environmental or biological samples with a flocculant, which alternatively can be after a substantial amount of a detergent is separated from the nucleic acid.
- PCR polymerase chain reaction
- nucleic acid hybridization inhibiting substances e.g., DNA-DNA hybridization
- kits for isolating a nucleic acid from environmental or biological samples and a kit for purifying a nucleic acid extracted from environmental or biological samples, which comprise a flocculant and instructions describing a method for use according to any of the methods described herein for isolating the nucleic acid.
- soil refers to environmental samples of soil, sediment, manure, compost, and the like, e.g., commercial potting mixtures, commercial soil amendments.
- the term also includes a broad range of organic carbon and nitrogen content and varying sand, silt and/or clay compositions.
- Soil includes any composition containing components commonly associated with habitable and uninhabitable areas of the earth and space, including for example varying descriptions, e.g., indoor dust, outdoor dust, dirt, mud, muck, silt, ground, compost, composting landfills at various depths.
- soil samples include but are not limited to landfill (e.g., 0-3 inches deep or 3-6 inches deep); late-stage compost; coffee compost; marine sediment; lake sediment; mud sediment; animal manure (e.g., horse manure); mulch, e.g., mulch top soil; the ocean floor, hillsides, mountaintops and may extend from the surface to any depth.
- the sample may be collected by any means using any commercially available or improvised method and tested directly.
- nucleic acid is extracted using a kit or method of the invention at the site of collection, or the sample may be stored before a nucleic acid is isolated therefrom.
- environment includes any environmental material, e.g., material contained in the earth and space, including space dust, airborne and waterborne locations and will include any organism, structure, and component considered alive, dead, dormant or inactive, whole, complete, undecaying and decaying that contains nucleic acid.
- Environmental and “environmental sample” include material and organisms that may be isolated from the environment as dust or suspended material collected by filtration.
- nucleic acid refers to one or more nucleic acids of any kind, including single- or double-stranded forms.
- a nucleic acid can be DNA and in one aspect can be RNA.
- nucleic acid is detected and/or isolated from one or more organisms present in a sample, e.g., a soil sample, examples of which include but are not limited to bacteria (e.g., Gram positive or Gram negative), yeast, fungi, algae, viruses (e.g., HIV) and nematodes.
- Nucleic acid, e.g., RNA and DNA, detected or isolated using a kit or method of the invention can be from any organism, including, but not limited to viruses, bacteriophage, plasmids, spores, yeast, fungi, algae, nematodes, protozoa, eukaryotic cells, prokaryotic cells and in general, single- and multicellular forms.
- DNA or RNA detected or isolated using a kit or method of the invention is not necessarily located within a specific organelle among prokaryotic members, but may be found in the cytoplasm, chloroplasts, mitochondria and nuclei of eukaryotic and multicellular organisms.
- RNA detected or isolated using a kit or method of the invention is found in a variety of organisms, including, but not limited to viruses, eukaryotic cells, prokaryotic cells and in general, single- and multicellular forms.
- RNA detected or isolated using a kit or method of the invention includes forms found in a multitude of biological forms, including but not limited to, messenger RNA in protein translation, ribosomal RNA in ribosomal protein translation, transfer RNA in protein translation, small interfering RNA and microRNA in gene regulation.
- Gram negative bacteria examples include but are not limited to Gram negative rods (e.g., anaerobes such as bacteroidaceae (e.g., Bacteroides fragilis), facultative anaerobes, enterobacteriaceae (e.g., Escherichia coli), vibrionaceae (e.g., Vibrio cholerae), pasteurellae (e.g., Haemophilus influenzae), and aerobes such as pseudomonadaceae (e.g., Pseudomonas aeruginosa); Gram negative cocci (e.g., aerobes such as Neisseriaceae (e.g., Neisseria meningitidis) and Gram negative obligate intracellular parasites (e.g., Rickettsiae (e.g., Rickettsia spp.).
- Gram negative rods e.g., anaerobes such as bacteroidace
- Gram negative bacteria families that can be detected and/or whose nucleic acid can be isolated include but are not limited to Acetobacteriaceae, Alcaligenaceae, Bacteroidaceae, Chromatiaceae, Enterobacteriaceae, Legionellaceae, Neisseriaceae, Nitrobacteriaceae, Pseudomonadaceae, Rhizobiaceae, Rickettsiaceae and Spirochaetaceae.
- Gram positive bacteria examples include but are not limited to A. globiformis, B. subtilis, C. renale, M. luteus, R. erythropolis, Ea39, Ben-28 and S. lividans.
- Gram positive bacteria that can be detected and/or whose nucleic acid can be isolated also are in groups that include, for example, Corynebacterium, Mycobacterium, Nocardia; Peptococcus (e.g., P. niger); Peptostreptococcus (e.g., Ps.
- anaerobius some species in the group form clumps and clusters; some species in the group form diplococci (the latter of which are distinguished by their ability to form butyrate); and some species in the group are capable of fermentation, reduction of nitrate, production of indole, urease, coagulase or catalase); Ruminococcus; Sarcina; Coprococcus; Arthrobacter (e.g., A. globiformis, A. citreus or A. nicotianae); Micrococcus (e.g., M. luteus (previously known as M. lysodeikticus), M. lylae, M. roseus, M. agilis, M.
- M. luteus previously known as M. lysodeikticus
- M. lylae M. roseus
- M. agilis M.
- Bacillus e.g., B. anthracis, B. azotoformans, B. cereus, B. coagulans, B. israelensis, B. larvae, B. mycoides, B. polymyxa, B. pumilis, B. stearothormophillus, B. subtilis, B. thuringiensis, B. validus, B. weihenstephanensis and B. pseudomycoides
- Sporolactobacillus Sporocarcina; Filibacter; Caryophanum and Desulfotomaculum.
- Clostridium which often include peritrichous flagellation, often degrade organic materials to acids, alcohols, CO 2 , H 2 and minerals (acids, particularly butyric acid, are frequent products of clostridial fermentation), and in one aspect form ellipsoidal or spherical endospores, which may or may not swell the sporangium.
- Species of Clostridium that can be detected and/or whose nucleic acid can be isolated include psychrophilic, mesophilic or thermophilic species, saccharolytic species, proteolytic species and/or specialist species, and those that are both saccharolytic and proteolytic species.
- Saccharolytic species of Clostridium that can be detected and/or whose nucleic acid can be isolated include but are not limited to Cl. aerotolerans, Cl. aurantibutyricum, Cl. beijerinckii, Cl. botulinum B,E,F*, Cl. butyricum, Cl. chauvoei, Cl. difficile, Cl. intestinale, Cl. novyi A, Cl. pateurianum, Cl. saccharolyticum, Cl. septicum, Cl. thermoaceticum, and Cl. thermosaccharolyticum.
- Proteolytic species of Clostridium that can be detected and/or whose nucleic acid can be isolated include but are not limited to Cl. argeninense, Cl. ghoni, Cl. limosum, Cl. putrefaciens, Cl. subterminale and Cl. tetani.
- Species that are proteolytic and saccharolytic that can be detected and/or whose nucleic acid can be isolated include but are not limited to Cl. acetobutylicum, Cl. bifermenans, Cl. botulinum A, B, F (prot.)*, Cl. botulinum C 1 D*, Cl. cadaveris, Cl. haemolyticum, Cl. novyi B, C, * Cl.
- Cl. botulinum is subdivided into a number of types according to the serological specificities of the toxins produced.
- Specialist Clostridium species that can be detected and/or whose nucleic acid can be isolated include but are not limited to Cl. acidiurici, Cl. irregularis, Cl. kluyveri, Cl. oxalicum, Cl. propionicum, Cl. sticklandii and Cl. villosum. These specificities are based on neutralization studies.
- Other Clostridium species that can be detected and/or whose nucleic acid can be isolated include those that produce botulinum toxins.
- Examples of fungi that can be detected and/or whose nucleic acid can be isolated using the kits and methods of the invention include but are not limited to Halocyphina villosa, Hypoxylon oceanicum, Verruculina enalia, Nia vibrissa, Antennospora quadricornuta, Lulworthia spp. and Aigialus parvus.
- Examples of algae that can be detected and/or whose nucleic acid can be isolated include but are not limited to brown algae (e.g., Phylum Phaeophycota Dictyota sp.
- Organisms that can be detected by the kits and processes of the invention in a sample include but are not limited to Pseudomonas spp., Serratia spp., Bacillus spp., Flavobacterium spp., Actinomycetes and fungi; in polluted soils include but are not limited to Pseudomonas spp.
- bacterium detected in soil samples for use in combating bioterrorism using methods and kits of the invention is Bacillus anthracis.
- kits of the invention have many medical and veterinary applications, e.g., for diagnosis, prognosis, epidemiology, inspection of contamination of materials (e.g., drugs, dressing, instruments, implants), foods (e.g., inspections of meat, vegetables, seafood, etc.), including medical and veterinary analysis of feces (including manure analysis for animals).
- Medical and veterinary applications include detection of soils, e.g., for bioterrorism purposes, e.g., anthrax, viruses, nematodes, and the like.
- Virus detection using the kits and methods of the invention can also analyze manure and soil, water, air and the like.
- kits and methods of the invention include variola, varicella, reovirus, retroviruses (e.g., HIV), viral hemorrhagic fevers (e.g., Ebola, Marburg, Machupo, Lassa), Variola major, viral encephalitis and the like, as listed in Table 1, below.
- the kits and methods of the invention can also be used to detect spores, toxins and biologically produced poisons, for example, by detecting Bacillus anthracis, anthrax spores are also detected (albeit, indirectly), detection of Clostridium perferinges implies presence of toxin, etc.
- pathogens and toxins that can be detected by kits and methods of the invention includes those listed in Table 1, below: Table 1
- any method for extracting the nucleic acid from a sample may be used, and multiple methods are known.
- a bead beating process can be utilized in which the soil sample is contacted with beads and vibration. Vibration can be introduced by any convenient means, such as by a sonication or a vortex apparatus using a Vortex Adapter (Mo Bio Laboratories, Carlsbad, CA), for example.
- extraction includes contacting the soil sample and/or nucleic acid with a detergent, examples of which include but are not limited to sodium dodecyl sulfate, sarkosyl, sodium lauryl sarcosinate, cetyltrimethylammonium bromide (CTAB, also known as hexadecyltrimethyl- ammonium bromide), cholic acid, deoxycholic acid and 4-amino-7-benzamidotaurocholic acid (BATC, also known as 2-[3a,12a-Dihydroxy-7-(4-aminobenzamido)-5b-(cholanoyl-24-amino)- ethanesulfonic acid]) polyethylene glycoltert-octylphenyl ether (Triton ® X-100), (1,1,3,3- tetramethylbutyl)phenyl-polyethylene glycol (Triton ® X-l 14).
- a detergent examples of which include but are not
- liquid extraction reagents are mixed in a closed container with the sample containing nucleic acid and the mixture is shaken by hand or applied to a mixing device, exemplified by a common laboratory device known as a vortex.
- the solid sample components are then separated in a non-specific manner by centrifugation from the liquid component and the nucleic acid is extracted from the liquid portion.
- a disintegration process is introduced to dissociate the environmental or biological sample and disrupt the organisms and components to facilitate nucleic acid release, thereby increasing the nucleic acid yield.
- This process does not remove nucleic acid contaminating material but instead increases the concentration of the inhibiting material into the media.
- the process of disruption increases the release of humic substances in the case of environmental samples such as soils while in plants, this method increases the amount of cellular debris along with the release of nucleic acids.
- nucleic acid extraction is enhanced by contacting the soil sample and/or nucleic acid with a detergent, examples of which include, but are not limited to, sodium dodecyl or lauryl sulfate (SDS), sarkosyl, sodium lauryl sarcosinate, cetyltrimethylammonium bromide (CTAB, also known as hexadecyltrimethylammonium bromide), cholic acid, deoxycholic acid and 4- amino-7-benzamidotaurocholic acid (BATC, also known as 2-[3a,12a-Dihydroxy-7-(4- aminobenzamido)-5b-(cholanoyl-24-amino)-ethanesulfonic acid]), polyethylene glycokert- octy
- a hot detergent and vortex lysis procedure is utilized.
- organic extractions have been used with varying success to partition nucleic acids from proteinaceous and non-proteinaceous contaminating substances.
- organic extraction reagents include, but are not limited to, phenol, ether, chloroform, ethanol and isopropyl alcohol. These reagents, alone or in combination, do not completely remove contaminating substances such as humic substances but instead increase the solubility of humic substances and create conditions for them to co-purify with nucleic acids and thus inhibit useful application following purification.
- the term "flocculant” as used in the methods and compositions of the invention refers to a substance that precipitates one or more components from solution.
- the terms “flocculant” and “precipitating reagent” refer to a material that will combine with a dissolved and/or suspended material in a reactive or passive manner such that the combined mass of the two in a solution will reach a critical point whereby the combined material will "precipitate”, i.e., become incapable of remaining suspended and “fall out” of solution.
- the flocculant can selectively precipitate certain components ("the precipitate”) from solution over others.
- the flocculant can be selected such that it does not precipitate a substantial amount of a nucleic acid from solution, but does precipitate a substantial amount of one or more substances that inhibit PCR or hybridization of an oligonucleotide to the nucleic acid.
- the flocculant precipitates a humic substance, a humic acid (the fraction of humic substances that is not soluble in water under acidic conditions (pH ⁇ 2) but that is soluble at higher pH values.
- Humic acid can be extracted from soil by various reagents and which is insoluble in dilute acid; humic acids are the major extractable component of soil humic substances), a fulvic acid (the fraction of humic substances that is soluble in water under all pH conditions; they remain in solution after removal of humic acid by acidification and/or humin (the fraction of humic substances that is not soluble in water at any pH value and in alkali).
- the precipitant is removed from solution by either mechanical or non-mechanical methods, resulting in a liquid solution with lowered substance content.
- flocculent and flocculating conditions are chosen to selectively precipitate certain components from solution over others.
- the flocculant in the current invention is selected and introduced in the purification process in a unique way such that its interaction with soil debris and detergent is significantly induced.
- humic acid humic acid
- HA humic acid
- flocculant used to practice the invention comprise ionically charged (e.g. cationic, anionic, or zwitterionic) chemical substances or synthetic polymers, or uncharged (e.g. cationic, anionic, or zwitterionic) chemical substances or synthetic polymers, or a combination thereof.
- the flocculant comprises a cationic chemical substance, an anionic chemical substance, a zwitterionic chemical substance, a non-charged chemical substance or a combination thereof.
- the cationic, anionic, zwitterionic or non-charged substance comprises a quaternary ammonium or tertiary amine containing polymer.
- the flocculant is selected from the group consisting of ammonium acetate, magnesium chloride (MgCl 2 ), ferric chloride (FeCl 3 ), a salt of iron, a salt of aluminum, calcium chloride (CaCl 2 ), a polyacrylamide, aluminum ammonium sulfate, derivatives thereof, and a combination thereof.
- a zwitterionic chemical substance comprises an amino acid (e.g., glycine, alanine; amino acids exist at zwitterions ("twin ions") at physiological pH), or any chemical (e.g., amino acid, small molecule or polymer) that would otherwise be nonionic at neutral pH (e.g. zwitterionic) but that will assume either a positive or negative charge at acidic or basic pH within the context of the invention.
- Zwitterions used in the methods and kits of the invention can be molecules that have ionizable groups that balance positive and negative charges at physiological pH. For example, both the amino group and the carboxyl group of each amino acid are ionizable, making them zwitterions.
- the carboxyl group (with a pK a of about 3) is deprotonated at physiological pH.
- the amino group is protonated at physiological pH.
- the pK a of ammonium ions is about 9.
- the step at which the flocculation appears is critical in improving the efficiency of the flocculation process and the way it differs from the existing art of flocculation.
- Flocculation is generically used in numerous other applications and this invention incorporates the understanding that the stage at which the flocculant is added can be critical.
- Humic substances which are ubiquitous in aquatic and terrestrial environments play an important role in metal reduction by acting as electron shuttles. The quinine moieties in humic substances are thought to act as electron acceptors. It is through these mechanisms that humic acid reacts with select groups of inorganic salts of iron and aluminum and brings about the process of flocculation or metal-humic complex.
- the methods of the invention time the introduction of the flocculating agent at a stage in the protocol where the majority of the detergents, suspended solids and proteins, which are mostly ionic in nature are removed completely or reduced to an insignificant percentage. This sets the stage for removing the humic substances through flocculation, which are predominantly in a dissolved state and are believed to be a major component in the sample milieu apart from nucleic acid. The humic substances are available for selective flocculation to leave the nucleic acid in solution.
- the flocculant used in the methods and compositions of the invention comprises a chemical substance such as a cationic chemical substance.
- the flocculant is selected from the group consisting of ammonium acetate, magnesium chloride (MgCl 2 ), ferric chloride (FeCl 3 ), calcium chloride (CaCl 2 ), inorganic salts of iron and aluminum, a polyacrylamide (e.g., SUPERFLOCTM, Cytec Industries), aluminum ammonium sulfate, derivatives thereof, and equivalents thereof (e.g., Braid et al., J. Microbiological Methods 52: 389-393 (2003)).
- a polyacrylamide e.g., SUPERFLOCTM, Cytec Industries
- aluminum ammonium sulfate e.g., Braid et al., J. Microbiological Methods 52: 389-393 (2003).
- a flocculant used in the methods and compositions of the invention comprises a cationic flocculant as disclosed, e.g., in U.S. Patent Nos. 3,002,960; 3,316,181; 3,686,109; 3,692,673; 3,374,143; 4,010,131; 4,451,628; 4,565,635; 4,702,844; 4,693,830; 4,695,453; 4,147,681;; 4,770,803; 5,552,316.
- a flocculant used in the methods and compositions of the invention comprises a cationic flocculant derived from alpha-beta unsaturated monomers.
- Detergents or surfactants can be used to practice the methods or kits of the invention.
- the nucleic acid is contacted with the flocculant after separating a substantial amount of the detergent from the nucleic acid.
- a detergent is separated from the nucleic acid by contacting the nucleic acid and detergent with a detergent specific precipitant (e.g., ammonium acetate precipitates the detergent sodium dodecyl sulfate) and separating the precipitated detergent by centrifugation.
- a detergent specific precipitant e.g., ammonium acetate precipitates the detergent sodium dodecyl sulfate
- a substantial amount of the flocculant is separated from the nucleic acid; this can be done by any convenient procedure.
- separation can be performed by contacting the flocculant and nucleic acid with a solid support under conditions in which the nucleic acid selectively binds to the solid support.
- the solid support comprises or consists of silica, and the nucleic acid adheres to the silica in the presence of a chaotropic substance (e.g., guanidinium chloride) and is eluted from the silica by removing the chaotrope and adding water.
- a chaotropic substance e.g., guanidinium chloride
- substantially amount refers to the separated substance being present in a solution containing the nucleic acid after separation in an undetectable amount, or in an amount less than about 60%, less than about 50%, less than about 40%, less than about 30%, less than about 20%, less than about 10%, less than about 5%, less than about 1%, less than about 0.1%, less than about 0.01%, less than about 0.001%, less than about 0.0001%, less than about 0.00001%, less than about 0.000001% by weight of the separated substance to the weight of the nucleic acid.
- the nucleic acid isolated by a method of the invention is utilized in a subsequent procedure, which can be performed after the nucleic acid is isolated (e.g., after the nucleic acid is separated from the flocculant) and in one aspect can be performed during the procedure of isolating the nucleic acid.
- a subsequent procedure which can be performed after the nucleic acid is isolated (e.g., after the nucleic acid is separated from the flocculant) and in one aspect can be performed during the procedure of isolating the nucleic acid.
- an oligonucleotide can be contacted with the nucleic acid.
- the oligonucleotide can be designed to hybridize to a particular nucleotide sequence potentially present in the nucleic acid.
- Nucleotide sequences for many organisms in soil samples are publicly available, e.g., NIH GenBank, and standard methods for designing and generating oligonucleotides are utilized to generate oligonucleotides that specifically hybridize to a nucleic acid of a particular organism, e.g., as described in Current Protocols In Molecular Biology (Ausubel, F.M., et al., eds. 2000) and Sambrook et al., "Molecular Cloning: A Laboratory Manual," 2nd ed. (1989).
- the oligonucleotides can be utilized in different types of procedures and analyses, including an amplification procedure (described hereafter).
- the invention provides a procedure in which multiple oligonucleotides are linked to a detectable label and contacted with the nucleic acid; the combination of oligonucleotides that hybridize to the nucleic acid is a signature for the type or types of organisms present in the sample.
- the isolated nucleic acid or a portion thereof is amplified, where amplification can be performed using a polymerase chain reaction (PCR) procedure, reverse transcription, rolling circle replication and ligase-chain reaction.
- PCR polymerase chain reaction
- the isolated nucleic acid can be substantially free of a substance that inhibits a PCR procedure (e.g., the isolated nucleic acid can be substantially free of a humic substance).
- PCR procedures are known (e.g., see U.S. Patent Nos.
- PCR processes are performed in cycles, where each cycle includes heat denaturation, in which hybrid nucleic acids dissociate; cooling, in which primer oligonucleotides hybridize; and extension of the oligonucleotides by a polymerase (i.e., Taq polymerase).
- a polymerase i.e., Taq polymerase
- An example of a PCR cyclical process that can be used in practicing the invention comprises treating the sample at 95 0 C for 5 minutes; repeating forty-five cycles of 95 0 C for 1 minute, 59 0 C for 1 minute, 10 seconds, and 72 0 C for 1 minute 30 seconds; and then treating the sample at 72 0 C for 5 minutes.
- PCR amplification products can be are stored for a time at a lower temperature (e.g., at 4 0 C) and can be frozen (e.g., at -2O 0 C) before analysis.
- Amplification products and DNA isolated from environmental and biological samples by the methods and kits of the invention can be detected by any suitable manner.
- PCR amplification products in a sample can be resolved and detected by gel electrophoresis (e.g., plate or capillary gels composed of polyacrylamide or agarose), where bands corresponding to amplification products can be resolved by size and visualized by a light-emitting dye that intercalates with nucleic acid products in the gel (e.g., ethidium bromide).
- gel electrophoresis e.g., plate or capillary gels composed of polyacrylamide or agarose
- bands corresponding to amplification products can be resolved by size and visualized by a light-emitting dye that intercalates with nucleic acid products in the gel (e.g., ethidium bromide).
- PCR amplification products can be quantified by determining signal intensities of bands on a gel (e.g., by scanning the gel with a commercially available densitometer).
- amplification products can be quantified by hybridization techniques (e.g., performing real time (RT)-PCR using commercially available TAQMAN® and LUX® products).
- a double-labeled oligonucleotide complementary to a PCR product can be utilized in the quantification procedure, where one or both labels can be a fluorescent molecule (e.g., a carboxyfluorescein dye (F AMTM or FAM- XTM) at the 5' end of the oligonucleotide and a carboxytetramethylrhodamine dye (TAMRATM) at the 3' end of the oligonucleotide (e.g., these and other fluorescent dyes are commercially available, e.g., SYNTHEGEN, LLC, Houston, Texas).
- F AMTM or FAM- XTM carboxyfluorescein dye
- TAMRATM carboxytetramethylrhodamine dye
- Lower limits of the PCR detection process can be determined by serially diluti
- an isolated nucleic acid is RNA, and in one aspect, the RNA is reverse transcribed, such that complementary DNA (cDNA) is generated.
- cDNA complementary DNA
- Methods and products for reverse transcribing RNA are known (e.g., SUPERSCRIPTTM II Reverse
- the cDNA in one aspect can be quantified, such as by using a method described above, and in one aspect the cDNA is quantified after the cDNA produced by the reverse transcription procedure is amplified.
- the isolated nucleic acid is contacted with a restriction enzyme.
- comparative restriction digests can be assessed to determine whether a restriction digest pattern signature for a particular organism or organisms is present in the soil sample.
- the isolated nucleic acid is analyzed by mass spectrometry. Mass spectrometry procedures are known (e.g., U.S. Patent Nos. 5,547,835; 5,605,798;
- the isolated nucleic acid is immobilized to a solid surface.
- solid surfaces include but are not limited to a glass slide or plate, a silicon wafer or chip, a well of a microtiter plate (e.g., 96-well or 384- well plate), and a plastic surface of a vessel suitable for growing cells.
- kits for isolating a nucleic acid from a sample e.g., an environmental or biological sample, which comprises a flocculant and instructions describing a method for use according to any of the methods of the invention for isolating the nucleic acid from the soil sample.
- the kit in one aspect further comprises a detergent, which can be utilized in a process for extracting nucleic acids from the soil.
- the kit comprises homogenizing methods and compositions, including beads (e.g., glass beads or garnet beads), and in one aspect includes an adaptor for connecting tubes containing the sample to a vortex apparatus (e.g., Vortex Adapter, Mo Bio Laboratories, Carlsbad, CA)..
- the kit in one aspect includes a solid support useful for separating a flocculant from a nucleic acid, such as a silica medium, where the solid support in one aspect can be in an apparatus adapted to fit into a tube for use in centrifugation.
- the kit comprises a chaotropic substance (e.g., guanidinium chloride), often used in a process for separating a flocculant from a nucleic acid.
- the kit comprises a solution useful for precipitating a detergent.
- the kit comprises one or more solutions useful for performing the method of use included in the instructions.
- the kit comprises one or more tube vessels useful for performing the method of use. Where tube vessels are included in the kit, the vessels can be sterile.
- the kit includes components useful for further processing the isolated nucleic acid.
- the kit includes one or more components selected from the group consisting of one or more oligonucleotides, free nucleotides and a polymerase capable of amplifying all or part of an isolated nucleic acid.
- the kit includes one or more oligonucleotides that hybridize to a bacterial nucleic acid, e.g., a Bacillus anthracis, or other agent associated with bioterrorism that contain DNA or RNA.
- Alternative embodiments comprise procedures and kits for purifying a nucleic acid already extracted from a sample, e.g., environmental or biological samples.
- Such procedures and kits are applicable to a nucleic acid extracted from environmental or biological samples using a kit or procedure different than one of this invention.
- these procedures and kits of the invention are useful for purifying contaminated nucleic acid preparations isolated from a sample, e.g., environmental or biological samples, such as soil samples (e.g., separating substances from the nucleic acid that inhibit downstream procedures).
- the purification procedures and kits can be useful for separating contaminants from the extracted nucleic acids, such as contaminant substances that inhibit PCR and/or hybridization of an oligonucleotide to the nucleic acid (e.g., a humic substance).
- the purification procedures are applicable to a variety of nucleic acid preparations, including those that do not yield detectable amplification products after performing PCR, and those that can be colored (e.g., nucleic acid preparations that are yellow to brown in color).
- a method for purifying a contaminated nucleic acid extracted from a sample e.g., environmental or biological samples, such as soil samples comprising contacting the nucleic acid with a flocculant.
- the flocculant is separated from the nucleic acid in a subsequent step, as described above.
- the nucleic acid in one aspect can be contacted with a detergent, and a substantial amount of the detergent can be separated from the nucleic acid before the nucleic acid is contacted with the flocculant.
- a substantial amount of the detergent in one aspect can be separated from the nucleic acid by contacting the detergent with a substance that selectively precipitates the detergent and then subjecting the mixture to centrifugation, which pellets the precipitated detergent and leaves the nucleic acid in the supernatant fraction.
- the invention provides DNA and RNA targeting techniques that allow in situ analysis of microbial communities in soil environments.
- RNA isolation using the methods and kits of the invention can make it possible to study mRNA expression levels that provide valuable information on functional activities of specific microbial genes within microbial populations in soil. Because the methods and kits of the invention can make it possible to identify, isolate and/or amplify total cell nucleic acid, mitochondrial, nuclear, chloroplast or other organelle nucleic acid, including RNA and DNA, can also be identified, isolated and/or amplified using the methods and kits of the invention. In order to study gene expression in soil, the invention provides a robust protocol for extraction of total, nondegraded RNA.
- the invention provides a reliable recovery process for messenger RNA (mRNA) from differing natural environments with microbial heterogeneity, variations in experimental conditions, differences in the interactions of DNA and RNA molecules with environmental sample matrices, adsorption characteristics of clay fractions to nucleic acids and the labile nature of RNA to nucleases and oxidation-reduction processes that occur naturally in soils and other natural environments.
- mRNA messenger RNA
- the invention provides a distinct departure from the traditional method of adding the flocculating reagent and detergent before sample lysis to provide a method whereby high organic content samples produce nucleic acid from contaminating substances.
- the invention provides for the use of flocculating materials for purifying nucleic acid from environmental and biological samples by addition of a flocculating material to a nucleic acid (and contaminant) containing sample following partial purification of the nucleic acid from the starting environmental and biological sample and its components (e.g. soil, cellular debris, humic substances and detergent).
- the invention provides a method for purifying a contaminated nucleic acid extracted from an environmental soil sample, which comprises contacting the nucleic acid with a flocculant.
- the flocculant is separated from the nucleic acid in a subsequent step as described above with the use of silica membranes.
- the nucleic acid purification process may include contact with a detergent, and in one embodiment, a substantial amount of the detergent is separated from the nucleic acid before the nucleic acid is contacted with the flocculant.
- a substantial amount of the detergent is separated from the nucleic acid by contacting the detergent with a substance that selectively precipitates the detergent.
- the precipitate is removed by passive settling or by subjecting the mixture to centrifugation, which pellets the precipitated detergent and leaves the nucleic acid in the supernatant fraction.
- the process described herein is not dependent upon, but may include the use of a component for facilitating sample disruption and nucleic acid liberation prior to or contemporaneous to flocculent addition to the sample (e.g., homogenizing beads). It should be noted that the use of a flocculating agent with a sample that does not contain contaminating substances will not affect the nucleic acid purity or use in downstream applications.
- the invention provides kits for separating nucleic acids either extracted directly from an environmental or biological sample, or for DNA previously purified by non- flocculating methods from samples containing contaminating substances that inhibit downstream nucleic acid application.
- the purification procedures and kits of the invention are applicable to a variety of nucleic acid preparations, including those that do not yield detectable amplification products after performing PCR and those whose refractive index indicate clear to colored (e.g., nucleic acid preparations that are yellow to brown in color) composition.
- the kits and methods of the invention are adaptable to a wide range of sample volume, mass and type and nucleic acid yield.
- Example 1 DNA Isolation from Up to 250 Milligram of Environmental Sample
- Nucleic acid from several different soil types was isolated and examined using the method describe herein.
- the kit and method were tested on soils, sediments, composts and manure representing a broad range of organic carbon and nitrogen content and varying sand/silt/clay compositions.
- the same kit was also tested and found to be effective in isolating DNA free of contaminants from plant tissues such as leaves, roots, stems and seed materials Specifically, for soils, there were nine samples, which included landfill 0-3 inches deep; landfill 3-6 inches deep; late-stage compost; coffee compost; marine sediment; lake sediment; mud sediment; horse manure and mulch-top soil.
- DNA was extracted from these samples using the method described herein and analyzed by agarose gel electrophoresis to determine DNA quality by visually identifying a discreet DNA band greater than 23,000 molecular weight (23 kbp). The presence of shorter DNA fragments is an indication of DNA breakage, or shearing, during the process.
- the usefulness of the purified DNA to downstream applications in part determined by whether the sample is substantially free from PCR-inhibiting substances, was assessed by PCR amplification using consensus primers specific for a 520 base pair (bp) region of eubacterial 16S ribosomal DNA.
- FIG. 1 DNA purified by the method described herein was characterized by agarose gel electrophoresis.
- Figure 1 Total genomic DNA isolated from 0.25 grams of representative soil types. DNA was analyzed by 0.8% TAE agarose gel electrophoresis, ethidium stained and photographed. Samples were obtained from landfill (0-3 inches deep, lane 1), landfill (3 - 6 inches deep, lane 2), late stage compost (lane 3), coffee compost (lane 4), marine sediment (lane 5), lake sediment (lane 6), mud sediment (lane 7), horse manure (lane 8) mulch topsoil (lane 9).
- M DNA molecular size marker.
- genomic DNA was isolated from all tested soil samples. PCR amplification of the isolated genomic DNA from Figure 2 using primers to eubacterial DNA indicated that PCR products were produced from each soil sample, indicating the nucleic isolation procedure described herein had successfully purified eubacterial genomic DNA.
- Figure 2 illustrates an agarose gel electrophoresis showing PCR amplified total genomic DNA isolated in Figure 1 , where the purified eubacterial genomic DNA was PCR amplified using primers to eubacterial DNA.
- M DNA molecular size marker.
- DNA was isolated from the soil types used in Figure 1 , using the ULTRACLEANTM Soil DNA Kit (Mo Bio Laboratories, Carlsbad, CA)
- Figure 3 shows PCR amplification of the genomic DNA using primers to eubacterial DNA.
- M DNA molecular size marker. Note that DNA isolated with the ULTRACELANTM Soil DNA Kit contained contaminants removed using the invention that prevented PCR amplification in 4 of the 9 tested samples.
- Example 2 provides evidence of the invention scalability.
- Example 2 Purification of DNA Extracted from Up to 10 Grams of Soil
- Example 3 Procedure for removing contaminants from nucleic acid
- nucleic acid that may be used in downstream processes from previously purified nucleic acid that has contaminating substances that have prevented use of the nucleic acid in a downstream application (e.g. PCR).
- the nucleic acid was isolated using the ULTRACLEAN MEGASOIL DNA ISOLATION KIT and processed using the procedure and reagents indicated below and analyzed ( Figure 7,). The nucleic acid was tested in PCR ( Figure 8). Nucleic acid was purified from 3 different environmental samples (identified by
- the nucleic acid in Figure 7 appears equivalent for each sample set following isopropanol precipitation and contaminant removal.
- Figure 7 shows the use of the nucleic acid in Figure 6 in a PCR procedure.
- the lanes labeled 8 ml and 1 * show PCR inhibition and input nucleic acid is unable to produce an amplification product.
- the lanes labeled 1 ⁇ which have been processed with the contaminant removal process described herein, show successful removal of the contaminant and PCR amplification product.
- RNA isolated from 8 different soil types as noted in Table 2, below, and run on a 1%, Ix TAE gel for 45 minutes at 100 v., see Figure 9. Table 2. List of soil samples used to isolate RNA
- RNA was isolated from several different soil types and examined using a method and described herein.
- the kit and method were tested on soils, sediments, composts and manure representing a broad range of organic carbon and nitrogen content and varying sand/silt/clay compositions. Specifically, there were eight samples, which included a heavily fertilized lawn soil, soil from a straw berry cultivated field in Southern California, a sediment fed by sea water, a commercially amended soil, city compost, soil from a corn field in Iowa, soil from rhizosphere region of a plant, and a sandy soil from east of San Diego County.
- the example below uses a vortex mechanical lysis process extraction/homogenization procedure and is incorporated to illustrate its use.
- RNA purified by the method described herein was characterized by agarose gel electrophoresis. Using the procedure disclosed above, RNA was isolated from all tested soil samples. RT-PCR amplification of the isolated RNA from Figure 9 using two different primer sets (one for Bacilli group and the other for Streptomycetes group) indicated that RT-PCR products were produced from each soil sample, indicating the RNA isolation procedure described herein had successfully purified RNA.
- RNA isolated was digested with RNase-free DNase and then purified by phenol: chloroform extraction followed by isopropanol precipitation.
- the DNA- free RNA was used undiluted in a RT-PCR reaction with a primer set specific for a 1200 bp fragment of microorganisms belonging to Streptomycetes group.
- total RNA isolated was digested with RNase-free DNase and then purified by phenolxhloroform extraction followed by isopropanol precipitation.
- the DNA-free RNA was used undiluted (1 ⁇ l/50 ⁇ l) in a RT-PCR reaction with a primer set specific for a 1200 bp fragment of microorganisms belonging to Streptomycetes group.
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES05856744.7T ES2529044T3 (en) | 2004-05-21 | 2005-05-20 | Kits and procedures to remove nucleic acid contaminants in environmental and biological samples |
CA2567599A CA2567599C (en) | 2004-05-21 | 2005-05-20 | Kits and processes for removing contaminants from nucleic acids in environmental and biological samples |
AU2005323451A AU2005323451B2 (en) | 2004-05-21 | 2005-05-20 | Kits and processes for removing contaminants from nucleic acids in environmental and biological samples |
EP05856744.7A EP1756136B1 (en) | 2004-05-21 | 2005-05-20 | Kits and processes for removing contaminants from nucleic acids in environmental and biological samples |
JP2007527515A JP5112064B2 (en) | 2004-05-21 | 2005-05-20 | Kits and methods for removing contaminants from nucleic acids in environmental and biological samples |
DK05856744.7T DK1756136T3 (en) | 2004-05-21 | 2005-05-20 | KIT AND METHODS FOR REMOVING IMPURITIES FROM nucleic acids in ENVIRONMENTAL AND BIOLOGICAL SAMPLES |
HK07109399.1A HK1102229A1 (en) | 2004-05-21 | 2007-08-28 | Kits and processes for removing contaminants from nucleic acids in environmental and biological samples |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57335804P | 2004-05-21 | 2004-05-21 | |
US60/573,358 | 2004-05-21 | ||
US57417904P | 2004-05-24 | 2004-05-24 | |
US60/574,179 | 2004-05-24 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006073472A2 true WO2006073472A2 (en) | 2006-07-13 |
WO2006073472A3 WO2006073472A3 (en) | 2006-09-21 |
Family
ID=36647922
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/017933 WO2006073472A2 (en) | 2004-05-21 | 2005-05-20 | Kits and processes for removing contaminants from nucleic acids in environmental and biological samples |
Country Status (9)
Country | Link |
---|---|
US (2) | US7459548B2 (en) |
EP (1) | EP1756136B1 (en) |
JP (1) | JP5112064B2 (en) |
AU (1) | AU2005323451B2 (en) |
CA (1) | CA2567599C (en) |
DK (1) | DK1756136T3 (en) |
ES (1) | ES2529044T3 (en) |
HK (1) | HK1102229A1 (en) |
WO (1) | WO2006073472A2 (en) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008043324A (en) * | 2006-07-18 | 2008-02-28 | Nisshin Seifun Group Inc | Primer and method for detecting bacteria by using the same |
EP2426201A1 (en) * | 2010-09-06 | 2012-03-07 | Qiagen GmbH | Method of isolating purified RNA with reduced DNA contaminations |
CN102605087A (en) * | 2012-03-30 | 2012-07-25 | 四川省畜牧科学研究院 | Pretreatment method for PCR (polymerase chain reaction) detection technique of common microorganisms in environment |
WO2014068083A1 (en) * | 2012-11-01 | 2014-05-08 | Novozymes A/S | Method for removal of dna |
US9017966B2 (en) | 2007-05-23 | 2015-04-28 | Nature Technology Corporation | E. coli plasmid DNA production |
WO2015132216A1 (en) * | 2014-03-07 | 2015-09-11 | IfP Privates Institut für Produktqualität GmbH | Method and kit of parts for extraction of nucleic acids |
WO2016026453A3 (en) * | 2014-08-20 | 2017-05-18 | 杨华卫 | Test kit and method for testing target nucleic acid in sample |
CN107151666A (en) * | 2016-03-03 | 2017-09-12 | 上海市农业科学院 | The extracting method of microbial DNA in a kind of water body |
WO2017209990A1 (en) * | 2016-05-31 | 2017-12-07 | Exxonmobil Upstream Research Company | METHODS FOR lSOLATING NUCLEIC ACIDS FROM SAMPLES |
WO2019180519A1 (en) * | 2018-03-17 | 2019-09-26 | Metagenom Bio Holdings Pte Ltd. | Method and kit for isolation of nucleic acids from a sample |
US10435735B2 (en) | 2014-03-07 | 2019-10-08 | Dna Genotek Inc. | Composition and method for stabilizing nucleic acids in biological samples |
US11002646B2 (en) | 2011-06-19 | 2021-05-11 | DNA Genotek, Inc. | Devices, solutions and methods for sample collection |
EP3881672A1 (en) | 2020-03-16 | 2021-09-22 | CNC Grondstoffen BV | Method of probing a mycelial substrate material |
US11242518B2 (en) | 2015-09-04 | 2022-02-08 | QIAGEN Sciences, LLP | Methods for co-isolation of nucleic acids and proteins |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7078224B1 (en) * | 1999-05-14 | 2006-07-18 | Promega Corporation | Cell concentration and lysate clearance using paramagnetic particles |
US7459548B2 (en) * | 2004-05-21 | 2008-12-02 | Mo Bio Laboratories, Inc. | Kits and processes for removing contaminants from nucleic acids in environmental and biological samples |
US7888011B2 (en) * | 2004-10-18 | 2011-02-15 | U.S. Genomics, Inc. | Methods for isolation of nucleic acids from prokaryotic spores |
EP1963526A4 (en) | 2005-12-09 | 2009-11-18 | Promega Corp | Nucleic acid purification with a binding matrix |
FR2894673B1 (en) * | 2005-12-14 | 2014-10-31 | Luc Montagnier | METHOD FOR CHARACTERIZING A BIOCHEMICAL ELEMENT HAVING BIOLOGICAL ACTIVITY BY ANALYZING LOW FREQUENCY ELECTROMAGNETIC SIGNALS |
DE602007009937D1 (en) * | 2006-02-24 | 2010-12-02 | Isp Investments Inc | USE OF PVPP FOR THE REMOVAL OF POLLUTANTS |
US20080003574A1 (en) * | 2006-06-28 | 2008-01-03 | Sigma-Aldrich Co. | Kits for RNA extraction |
EP1873241A1 (en) * | 2006-06-30 | 2008-01-02 | Qiagen AS | Process for isolating nucleic acids |
US20080096188A1 (en) * | 2006-10-19 | 2008-04-24 | U.S. Environmental Protection Agency Epa | Method to predict degradation of a landfill |
US20090204187A1 (en) * | 2008-02-12 | 2009-08-13 | Mankovitz Roy J | Soil-based compositions and methods for removal of toxins from mammals |
GB0814570D0 (en) | 2008-08-08 | 2008-09-17 | Diagnostics For The Real World | Isolation of nucleic acid |
US8405379B1 (en) | 2008-09-18 | 2013-03-26 | Luc Montagnier | System and method for the analysis of DNA sequences in biological fluids |
CA2745781A1 (en) * | 2008-12-03 | 2010-06-10 | Integrated Nano-Technologies, Llc | Universal biological sample processing |
ES2393662T3 (en) * | 2009-01-20 | 2012-12-27 | F. Hoffmann-La Roche Ag | Cryogenic container |
US9347086B2 (en) | 2009-04-03 | 2016-05-24 | Integrated Nano-Technologies, Llc | Method and system for sample preparation |
AU2010232396B2 (en) * | 2009-04-03 | 2014-03-20 | Integrated Nano-Technologies, Inc. | Multi-chamber rotating valve |
ES2628453T3 (en) * | 2009-05-22 | 2017-08-02 | Integrated Nano-Technologies, Inc. | Method and system for sample preparation |
CA2765167A1 (en) * | 2009-06-12 | 2010-12-16 | Nanectis Biotechnologies | A highly sensitive method for detection of viral hiv dna remaining after antiretroviral therapy of aids patients |
US8222397B2 (en) | 2009-08-28 | 2012-07-17 | Promega Corporation | Methods of optimal purification of nucleic acids and kit for use in performing such methods |
US8039613B2 (en) | 2009-08-28 | 2011-10-18 | Promega Corporation | Methods of purifying a nucleic acid and formulation and kit for use in performing such methods |
JP5574221B2 (en) * | 2010-02-22 | 2014-08-20 | 独立行政法人酒類総合研究所 | Method for detecting microorganism-derived DNA contained in brewed sake |
JP2013523143A (en) * | 2010-04-08 | 2013-06-17 | キアゲン ゲーエムベーハー | Methods for isolating and purifying nucleic acids |
DE102010036111B4 (en) | 2010-09-01 | 2013-08-29 | Bundesrepublik Deutschland (Bundesamt für Ausrüstung, Informationstechnik und Nutzung der Bundeswehr) | Pretreatment process for the isolation and concentration of nucleic acids from an environmental sample |
GB201112140D0 (en) | 2011-07-14 | 2011-08-31 | Dna Electronics | Nucleic acid amplification |
KR101935367B1 (en) | 2012-07-26 | 2019-01-04 | 삼성전자주식회사 | Method for enhancing efficiency and sensitivity in nucleic acid amplification from biological materials using ionic liquids |
CN104919035B (en) | 2012-12-21 | 2017-08-11 | 精密公司 | Portable fluorescence detecting system and micro- determination box |
CA2911195A1 (en) * | 2013-04-05 | 2014-10-09 | Mo Bio Laboratories, Inc. | Kits and methods for isolating protein from biological and environmental samples |
EP2994543B1 (en) | 2013-05-07 | 2018-08-15 | Micronics, Inc. | Device for preparation and analysis of nucleic acids |
WO2014182844A1 (en) | 2013-05-07 | 2014-11-13 | Micronics, Inc. | Microfluidic devices and methods for performing serum separation and blood cross-matching |
US10190153B2 (en) | 2013-05-07 | 2019-01-29 | Micronics, Inc. | Methods for preparation of nucleic acid-containing samples using clay minerals and alkaline solutions |
JP6385201B2 (en) * | 2013-08-31 | 2018-09-05 | 栄研化学株式会社 | Sample preparation method and reagent kit suitable for nucleic acid amplification |
WO2015154013A1 (en) * | 2014-04-03 | 2015-10-08 | The Board Of Regents For Oklahoma State University | System and method for dna extraction from samples containing humic acids |
ES2878948T3 (en) | 2014-06-12 | 2021-11-19 | Biomerieux Deutschland Gmbh | Unmask endotoxins in solution |
SI3155424T1 (en) | 2014-06-12 | 2018-04-30 | Hyglos Invest Gmbh | Unmasking endotoxins in solution |
US9528105B2 (en) | 2014-09-04 | 2016-12-27 | Techlab, Inc. | Nucleic acid extraction using organic solvents to remove inhibitors |
WO2017044827A1 (en) * | 2015-09-10 | 2017-03-16 | Life Technologies Corporation | Purification of nucleic acid from environmental or biological samples |
US10895666B2 (en) | 2016-07-01 | 2021-01-19 | Exxonmobil Upstream Research Company | Methods for identifying hydrocarbon reservoirs |
DE102017222295B4 (en) | 2017-12-08 | 2019-12-05 | Axagarius Gmbh & Co. Kg | Kits and methods for removing contaminants from a sample containing nucleic acid |
WO2019209597A1 (en) * | 2018-04-24 | 2019-10-31 | Qiagen Sciences Llc | Nucleic acid isolation and inhibitor removal from complex samples |
EP3820987A4 (en) * | 2018-07-11 | 2022-07-20 | Monsanto Technology LLC | Extraction of polynucleotides |
EP3844301A1 (en) * | 2018-08-30 | 2021-07-07 | GlaxoSmithKline Intellectual Property Development Ltd | Methods of detecting nucleic acid |
CN110129375A (en) * | 2019-05-15 | 2019-08-16 | 辽宁石油化工大学 | A kind of preparation method of microbial flocculant |
KR102370468B1 (en) * | 2020-03-18 | 2022-03-03 | 재단법인대구경북과학기술원 | A composition and a method for removal of residual anionic surfactant, protein-detergent complexes, and micelles, in biological tissues |
DE102020109837B3 (en) | 2020-04-08 | 2020-12-31 | Axagarius Gmbh & Co. Kg | Isolation of nucleic acids from environmental samples using magnetic particles |
CN113025686B (en) * | 2021-03-12 | 2023-07-28 | 江苏吉诺思美精准医学科技有限公司 | Virus RNA releasing agent, kit and application thereof |
CN113186037B (en) * | 2021-04-23 | 2022-12-13 | 山东博弘基因科技有限公司 | Nucleic acid scavenger |
WO2023023051A2 (en) * | 2021-08-16 | 2023-02-23 | The Regents Of The University Of California | Rapid, sensitive detection of nucleic acid sequences in environmental samples |
KR102690427B1 (en) * | 2022-06-29 | 2024-07-31 | 주식회사 어큐진 | Simultaneous extraction kit of DNA and RNA from single cells and Simultaneous extraction process using the same kit |
CN115125174B (en) * | 2022-07-19 | 2023-05-26 | 广东省科学院动物研究所 | Lead-resistant bacillus pumilus and application thereof |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
US5547835A (en) | 1993-01-07 | 1996-08-20 | Sequenom, Inc. | DNA sequencing by mass spectrometry |
US5605798A (en) | 1993-01-07 | 1997-02-25 | Sequenom, Inc. | DNA diagnostic based on mass spectrometry |
US5656493A (en) | 1985-03-28 | 1997-08-12 | The Perkin-Elmer Corporation | System for automated performance of the polymerase chain reaction |
US5849542A (en) | 1993-11-17 | 1998-12-15 | Amersham Pharmacia Biotech Uk Limited | Primer extension mass spectroscopy nucleic acid sequencing method |
US5869242A (en) | 1995-09-18 | 1999-02-09 | Myriad Genetics, Inc. | Mass spectrometry to assess DNA sequence polymorphisms |
US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
US6194144B1 (en) | 1993-01-07 | 2001-02-27 | Sequenom, Inc. | DNA sequencing by mass spectrometry |
WO2002055737A1 (en) | 2000-12-06 | 2002-07-18 | Clingenix, Inc. | Compositions and methods for dna purification from whole blood |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3002960A (en) * | 1958-08-18 | 1961-10-03 | American Cyanamid Co | Polyacrylamide preparation |
GB985084A (en) * | 1963-05-22 | 1965-03-03 | Us Rubber Co | Moulding apparatus and process for making the same |
US3374143A (en) * | 1964-06-11 | 1968-03-19 | Nalco Chemical Co | Method of improving operational efficiency of white water recovery system by treatment with anionic copolymers of acrylic acid salts and acrylamide |
US3686109A (en) * | 1970-09-24 | 1972-08-22 | Hercules Inc | Aqueous formulation of water soluble cationic or anionic vinyl addition polymers with water soluble condensation polyamides |
US3692673A (en) * | 1971-02-12 | 1972-09-19 | Lubrizol Corp | Water-soluble sulfonate polymers as flocculants |
US4010131A (en) * | 1974-07-08 | 1977-03-01 | Nalco Chemical Company | Quaternary modified acrylamide polymers |
US4147681A (en) | 1976-02-24 | 1979-04-03 | Calgon Corporation | Stable, self-inverting water-in-oil emulsions |
US4174681A (en) * | 1977-07-18 | 1979-11-20 | The Bendix Corporation | Two-group/simultaneous full injection conversion system for multiple cylinder engines |
FR2516397B1 (en) * | 1981-11-16 | 1988-01-15 | Rhone Poulenc Spec Chim | FLOCCULATION ADDITIVE AND PROCESS FOR THE PURIFICATION OF WATER |
US4451628A (en) * | 1982-09-13 | 1984-05-29 | Celanese Corporation | Process for preparing low molecular weight water-soluble polymers by copolymerizing with water-soluble monomers a calculated quantity of methallylsulfonate monomer |
DE3583559D1 (en) * | 1984-08-15 | 1991-08-29 | Allied Colloids Ltd | WATER-SOLUBLE POLYMERS. |
US4693830A (en) * | 1985-01-04 | 1987-09-15 | The Dow Chemical Company | Flocculants for brine-containing systems |
US4695453A (en) * | 1985-01-24 | 1987-09-22 | Henkel Corporation | Thickened alcoholic antimicrobial compositions |
US4770803A (en) * | 1986-07-03 | 1988-09-13 | The Lubrizol Corporation | Aqueous compositions containing carboxylic salts |
US6027750A (en) * | 1986-09-04 | 2000-02-22 | Gautsch; James | Systems and methods for the rapid isolation of nucleic acids |
US5069893A (en) | 1988-11-03 | 1991-12-03 | Handy Chemicals Limited | Polymeric basic aluminum silicate-sulphate |
DE69222013T2 (en) * | 1991-12-16 | 1998-01-29 | Ciba Geigy Ag | Endoplasmic reticulum-constant recombinant dibasic endoprotease and its uses |
US5552316A (en) * | 1993-06-04 | 1996-09-03 | Environmental Marketing Services, Ltd. | Clarifying E. coli fermentation broths with a combination of anionic and cationic flocculants |
US5637687A (en) * | 1993-08-31 | 1997-06-10 | Wiggins; James C. | Methods and compositions for isolating nucleic acids |
GB9425138D0 (en) | 1994-12-12 | 1995-02-08 | Dynal As | Isolation of nucleic acid |
US6268492B1 (en) * | 1998-08-10 | 2001-07-31 | Chiron Corporation | Methods for purifying non-chromosomal nucleic acid molecules from cells |
JP2001333774A (en) * | 2000-03-21 | 2001-12-04 | Nippon Gene Co Ltd | Method for extracting nucleic acid |
JP2001224371A (en) * | 2000-12-18 | 2001-08-21 | Sentan Seimei Kagaku Kenkyusho:Kk | Method of detecting or measuring hepatitis c virus (hcv) |
JP3904185B2 (en) * | 2001-06-21 | 2007-04-11 | キッコーマン株式会社 | Glutaminase, glutaminase gene, novel recombinant DNA and method for producing glutaminase |
JP2003250584A (en) * | 2001-12-27 | 2003-09-09 | National Institute Of Advanced Industrial & Technology | Carboxypeptidase gene |
GB0212825D0 (en) * | 2002-05-31 | 2002-07-10 | Dna Res Innovations Ltd | Methods compositions and kits for cell separation |
CA2498518A1 (en) * | 2002-09-13 | 2004-03-25 | Valentis, Inc. | Apparatus and method for preparative scale purification of nucleic acids |
US7459548B2 (en) * | 2004-05-21 | 2008-12-02 | Mo Bio Laboratories, Inc. | Kits and processes for removing contaminants from nucleic acids in environmental and biological samples |
-
2005
- 2005-05-20 US US11/134,849 patent/US7459548B2/en active Active
- 2005-05-20 AU AU2005323451A patent/AU2005323451B2/en active Active
- 2005-05-20 CA CA2567599A patent/CA2567599C/en active Active
- 2005-05-20 JP JP2007527515A patent/JP5112064B2/en active Active
- 2005-05-20 WO PCT/US2005/017933 patent/WO2006073472A2/en active Application Filing
- 2005-05-20 ES ES05856744.7T patent/ES2529044T3/en active Active
- 2005-05-20 EP EP05856744.7A patent/EP1756136B1/en active Active
- 2005-05-20 DK DK05856744.7T patent/DK1756136T3/en active
-
2007
- 2007-08-28 HK HK07109399.1A patent/HK1102229A1/en unknown
-
2008
- 2008-12-01 US US12/326,018 patent/US20090111159A1/en not_active Abandoned
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4683202B1 (en) | 1985-03-28 | 1990-11-27 | Cetus Corp | |
US5656493A (en) | 1985-03-28 | 1997-08-12 | The Perkin-Elmer Corporation | System for automated performance of the polymerase chain reaction |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683195B1 (en) | 1986-01-30 | 1990-11-27 | Cetus Corp | |
US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
US5605798A (en) | 1993-01-07 | 1997-02-25 | Sequenom, Inc. | DNA diagnostic based on mass spectrometry |
US5547835A (en) | 1993-01-07 | 1996-08-20 | Sequenom, Inc. | DNA sequencing by mass spectrometry |
US5691141A (en) | 1993-01-07 | 1997-11-25 | Sequenom, Inc. | DNA sequencing by mass spectrometry |
US6194144B1 (en) | 1993-01-07 | 2001-02-27 | Sequenom, Inc. | DNA sequencing by mass spectrometry |
US5849542A (en) | 1993-11-17 | 1998-12-15 | Amersham Pharmacia Biotech Uk Limited | Primer extension mass spectroscopy nucleic acid sequencing method |
US6043031A (en) | 1995-03-17 | 2000-03-28 | Sequenom, Inc. | DNA diagnostics based on mass spectrometry |
US5869242A (en) | 1995-09-18 | 1999-02-09 | Myriad Genetics, Inc. | Mass spectrometry to assess DNA sequence polymorphisms |
US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
WO2002055737A1 (en) | 2000-12-06 | 2002-07-18 | Clingenix, Inc. | Compositions and methods for dna purification from whole blood |
Non-Patent Citations (5)
Title |
---|
"Current Protocols In Molecular Biology", 2000 |
BRAID ET AL., J. MICROBIAL. METHODS, vol. 52, 2003, pages 389 - 393 |
DIJKMANS ET AL., MICROBIAL RELEASES: VIRUSES, BACTERIA AND FUNGI, vol. 2, 1993, pages 29 - 34 |
SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", 1989 |
See also references of EP1756136A4 |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008043324A (en) * | 2006-07-18 | 2008-02-28 | Nisshin Seifun Group Inc | Primer and method for detecting bacteria by using the same |
US9487789B2 (en) | 2007-05-23 | 2016-11-08 | Nature Technology Corporation | E. coli plasmid DNA production |
US9017966B2 (en) | 2007-05-23 | 2015-04-28 | Nature Technology Corporation | E. coli plasmid DNA production |
US9487788B2 (en) | 2007-05-23 | 2016-11-08 | Nature Technology Corporation | E. coli plasmid DNA production |
US9725725B2 (en) | 2007-05-23 | 2017-08-08 | Nature Technology Corporation | E. coli plasmid DNA production |
WO2012032034A1 (en) * | 2010-09-06 | 2012-03-15 | Qiagen Gmbh | Method of isolating purified rna with reduced dna contaminations |
EP2426201A1 (en) * | 2010-09-06 | 2012-03-07 | Qiagen GmbH | Method of isolating purified RNA with reduced DNA contaminations |
US9487550B2 (en) | 2010-09-06 | 2016-11-08 | Qiagen Gmbh | Method of isolating purified RNA with reduced DNA contaminations |
US11592368B2 (en) | 2011-06-19 | 2023-02-28 | DNA Genotek, Inc. | Method for collecting and preserving a biological sample |
US11549870B2 (en) | 2011-06-19 | 2023-01-10 | DNA Genotek, Inc. | Cell preserving solution |
US11002646B2 (en) | 2011-06-19 | 2021-05-11 | DNA Genotek, Inc. | Devices, solutions and methods for sample collection |
US11536632B2 (en) | 2011-06-19 | 2022-12-27 | DNA Genotek, Inc. | Biological collection system |
CN102605087A (en) * | 2012-03-30 | 2012-07-25 | 四川省畜牧科学研究院 | Pretreatment method for PCR (polymerase chain reaction) detection technique of common microorganisms in environment |
CN104797590A (en) * | 2012-11-01 | 2015-07-22 | 诺维信公司 | Method for removal of DNA |
WO2014068083A1 (en) * | 2012-11-01 | 2014-05-08 | Novozymes A/S | Method for removal of dna |
US11198899B2 (en) | 2014-03-07 | 2021-12-14 | Dna Genotek Inc. | Composition and method for stabilizing nucleic acids in biological samples |
US10106838B2 (en) | 2014-03-07 | 2018-10-23 | IfP Privates Institut für Produktqualität GmbH | Method and kit of parts for extraction of nucleic acids |
US10435735B2 (en) | 2014-03-07 | 2019-10-08 | Dna Genotek Inc. | Composition and method for stabilizing nucleic acids in biological samples |
WO2015132216A1 (en) * | 2014-03-07 | 2015-09-11 | IfP Privates Institut für Produktqualität GmbH | Method and kit of parts for extraction of nucleic acids |
WO2016026453A3 (en) * | 2014-08-20 | 2017-05-18 | 杨华卫 | Test kit and method for testing target nucleic acid in sample |
US10494665B2 (en) | 2014-08-20 | 2019-12-03 | Huawei Yang | Test kit and method for testing target nucleic acid in sample |
US11242518B2 (en) | 2015-09-04 | 2022-02-08 | QIAGEN Sciences, LLP | Methods for co-isolation of nucleic acids and proteins |
US11814618B2 (en) | 2015-09-04 | 2023-11-14 | Qiagen Sciences, Llc | Methods for co-isolation of nucleic acids and proteins |
CN107151666A (en) * | 2016-03-03 | 2017-09-12 | 上海市农业科学院 | The extracting method of microbial DNA in a kind of water body |
WO2017209990A1 (en) * | 2016-05-31 | 2017-12-07 | Exxonmobil Upstream Research Company | METHODS FOR lSOLATING NUCLEIC ACIDS FROM SAMPLES |
WO2019180519A1 (en) * | 2018-03-17 | 2019-09-26 | Metagenom Bio Holdings Pte Ltd. | Method and kit for isolation of nucleic acids from a sample |
EP3881672A1 (en) | 2020-03-16 | 2021-09-22 | CNC Grondstoffen BV | Method of probing a mycelial substrate material |
Also Published As
Publication number | Publication date |
---|---|
JP2008500066A (en) | 2008-01-10 |
CA2567599C (en) | 2015-07-21 |
DK1756136T3 (en) | 2015-01-19 |
WO2006073472A3 (en) | 2006-09-21 |
AU2005323451B2 (en) | 2010-11-18 |
US20050282202A1 (en) | 2005-12-22 |
CA2567599A1 (en) | 2006-07-13 |
US20090111159A1 (en) | 2009-04-30 |
EP1756136A4 (en) | 2010-10-06 |
JP5112064B2 (en) | 2013-01-09 |
HK1102229A1 (en) | 2007-11-09 |
EP1756136B1 (en) | 2014-10-29 |
US7459548B2 (en) | 2008-12-02 |
AU2005323451A1 (en) | 2006-07-13 |
ES2529044T3 (en) | 2015-02-16 |
EP1756136A2 (en) | 2007-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2005323451B2 (en) | Kits and processes for removing contaminants from nucleic acids in environmental and biological samples | |
Rajendhran et al. | Strategies for accessing soil metagenome for desired applications | |
US7893251B2 (en) | Methods for selective isolation of nucleic acids from microbial cells present in samples containing higher eukaryotic cells and/or tissues | |
Roose-Amsaleg et al. | Extraction and purification of microbial DNA from soil and sediment samples | |
Mahuku | A simple extraction method suitable for PCR-based analysis of plant, fungal, and bacterial DNA | |
US20180195057A1 (en) | Purification of nucleic acid from environmental or biological samples | |
US9145553B2 (en) | Method for isolating nucleic acids | |
Bergmann et al. | Influence of DNA isolation on Q-PCR-based quantification of methanogenic Archaea in biogas fermenters | |
Amita et al. | Qualitative evaluation of mycobacterial DNA extraction protocols for polymerase chain reaction | |
JP2004534515A (en) | Compositions and methods for extracting nucleic acids | |
US20220011202A1 (en) | Kits and methods for isolating protein from biological and environmental samples | |
US20120171728A1 (en) | Process for amplifying dna using tetratethylene glycol, kit of parts therefor and use thereof | |
JP4665124B2 (en) | Method for recovering DNA from environmental samples | |
WO2010146026A1 (en) | Improvement of low-biomass soil dna/rna extraction yield and quality | |
US7074565B2 (en) | Preparation of DNA-containing extract for PCR amplification | |
US20130023656A1 (en) | Method for selective isolation and purification of nucleic acids | |
JP2006067890A (en) | Method for extracting nucleic acid and nucleic acid-extracting kit | |
JP2005073643A (en) | Method for extracting dna originating from microorganism | |
Tweten | Testing noninvasive methods for extracting DNA from degraded wildlife scat | |
Hurt Jr et al. | Method for isolating nucleic acids | |
Bahkali et al. | In-house protocol for isolation of restrictable and amplifiable genomic DNA from plants, fungi and bacteria | |
JPWO2006088030A1 (en) | Nucleic acid extraction method, nucleic acid extraction agent, and nucleic acid extraction kit | |
JPH10201500A (en) | Detection of yeast and actinomycetes by direct extraction of dna from yeast and actinomycetes in environment | |
Huynh | Probing the Changes of Microbial Diversity with Land Use Changes on the Cumberland Plateau |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2567599 Country of ref document: CA Ref document number: 2007527515 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005856744 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005323451 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3666/KOLNP/2006 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2005323451 Country of ref document: AU Date of ref document: 20050520 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005323451 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2005856744 Country of ref document: EP |